Reneo Pharmaceuticals

Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.

Reneo Pharmaceuticals, Inc. - Common Stock

News

IPOs

GHRS

GH Research Shares Will Open For Quote At 9:50 a.m. EDT, Expected To Open For Trade After 10 a.m. EDT; IPO Priced At $16/Share

BlackBerry Ltd (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bb#NYSE">BB</a>) shares are trading lower by 3.6% at $12.22 Friday morning after the software company reported first-quarter earnings Thursday.&nbsp;
BlackBerry&#39;s total company revenue for the&nbsp;first quarter&nbsp;of fiscal 2022 was&nbsp;$174 million and total company gross margin was&nbsp;66%.
Following the earnings results, Canaccord Genuity analyst Michael Walkley downgraded&nbsp;BlackBerry from Hold to Sell.
CIBC analyst Todd Coupland downgraded&nbsp;BlackBerry from Neutral to Underperform and raised&nbsp;the price target from&nbsp;$9&nbsp;to&nbsp;$11.
BlackBerry is now exclusively a software provider with a stated goal of end-to-end secure communication for enterprises. The firm provides endpoint management and protection to enterprises, specializing in regulated industries like government, as well as embedded software to the automotive, medical, and industrial markets.
BlackBerry has a 52-week high of $28.77 and a 52-week low of $4.37.

Short Ideas

Movers

Trading Ideas

Why BlackBerry Shares Are Trading Lower Today

GRPH

Graphite Bio Shares Will Open For Quote At 10:10 a.m. EDT, Expected To Open For Trade After 10:20 a.m. EDT; IPO Priced At $17/Share

<ul>
<li>CareDx (CDNA) - 19,839</li>
<li>Castle Biosciences (CSTL) - 11,300</li>
<li>Pluristem Therapeutics (PSTI) - 25,339</li>
<li>Galileo Acquisition (GLEO) - 4,200</li>
<li>Pure Storage (PSTG) - 400</li>
</ul>

Hedge Funds

General

CDNA

CSTL

GLEO

PSTG

PSTI

Cathie Wood's ARK Invest Posts Fund Sales For Thursday, June 24, 2021: CDNA, CSTL, PSTI, GLEO, PSTG

<ul>
<li>Quantum-Si (QSI) - 95,199 Shares</li>
</ul>

Cathie Wood's ARK Invest Posts Fund Purchases For Thursday, June 24, 2021: QSI

Stifel analyst J. Bruce Chan maintains FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) with a Buy and raises the price target from $339 to $344.

Price Target

Analyst Ratings

Stifel Maintains Buy on FedEx, Raises Price Target to $344

IKNX

IKNONICS Shares To Resume Trade At 9:10 a.m. EDT

Offerings

GLBS

Globus Maritime Prices 10M Share Offering At $5/Share

Virgin Galactic Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/spce#NYSE">SPCE</a>) has received approval from the Federal Aviation Administration to fly passengers into space.
What Happened: In updating the company&rsquo;s 2016 commercial space transportation operator license, the FAA made history in its first licensing approval for a spaceline to carry customers in flight.
The company said the updated license followed the analysis of data from a May 22 space flight of its VMS Eve and VSS Unity, which was its third crewed spaceflight and the first to launch from Spaceport America, New Mexico. The flight achieved a speed of Mach 3 and reached space at an altitude of 55.5 miles, the company added.
&ldquo;We&rsquo;re incredibly pleased with the results of our most recent test flight, which achieved our stated flight test objectives,&rdquo; said Michael Colglazier, CEO of Virgin Galactic. &ldquo;The flight performed flawlessly, and the results demonstrate the safety and elegance of our flight system.
&ldquo;Today&rsquo;s approval by the FAA of our full commercial launch license, in conjunction with the success of our May 22 test flight, give us confidence as we proceed toward our first fully crewed test flight this summer.&rdquo;
The company is planning for three test flights. No schedule was announced for possible passenger flights.
See Also: <a href="https://www.youtube.com/watch?v=JO53e-Mqan0">Stock Market Live: It&#39;s Russell Rebalance Day!</a>
Why It Matters: Virgin Galactic is the latest company advocating for commercial passenger excursions into space.
Earlier this month, Amazon.com (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amzn#NASDAQ">AMZN</a>) Founder and CEO Jeff Bezos <a href="https://www.benzinga.com/news/21/06/21448828/jeff-bezos-will-travel-to-space-on-blue-origin-flight">announced</a>&nbsp;he would be among the passengers in a July 20 excursion by his Blue Space company that will travel from Texas to the edge of outer space and back.
And the privately-owned Florida-based Space Perspective is <a href="https://www.benzinga.com/news/21/06/21705863/who-wants-to-go-up-up-and-away-in-hydrogen-balloon-to-space">seeking reservations</a> for the 2024 liftoff via Spaceship Neptune, a hydrogen-supported 650-foot-tall balloon that will carry a passenger capsule above the Earth&rsquo;s atmosphere.
SPCE Price Action: Virgin Galactic rose by 12% in premarket trading after the announcement. The stock closed Thursday at $40.26, sandwiched between its 52-week high of $62.80 and its 52-week low of $14.27.
Photo: Land Rover Mena / Flickr Creative Commons.

Travel

Global

AMZN

SPCE

Virgin Galactic Scores FAA Approval To Take Passengers Into Space

Management

FSTR

LB Foster Reports Pres, CEO Robert Bauer To Retire; Names John Kasal Successor

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

OPRA

Opera To Integrate Celo Native Asset, Celo Dollar And Celo Euro Into Its Crypto Wallet

Y-mAbs Therapeutics, Inc. (the &ldquo;Company&rdquo; or &ldquo;Y-mAbs&rdquo;) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the Committee for Orphan Medicinal Products (&ldquo;COMP&rdquo;) of the European Medicines Agency (&ldquo;EMA&rdquo;) has recommended the granting of orphan medicinal product designation (&ldquo;OMPD&rdquo;) in the European Union (&ldquo;EU&rdquo;) for 177Lu-omburtamab-DTPA for the treatment of medulloblastoma. The positive opinion from the EMA&#39;s COMP has been sent to the European Commission (&ldquo;EC&rdquo;), which is expected to grant the orphan drug designation within 30 days.
Obtaining OMPD for 177Lu-omburtamab-DTPA is part of an overall plan to expand the Company&rsquo;s European development programs and ultimately obtain orphan drug exclusivity to protect 177Lu-omburtamab-DTPA for the treatment of medulloblastoma in the EU.
Under the EMA&rsquo;s Regulation (EC) No. 141/2000 an orphan medicinal product designation gives companies access to protocol assistance and guidance on preparing a dossier that will meet European regulatory requirements and thereby maximize the chance of approval at the time of marketing authorization. Once approved, an orphan drug is also granted 10 years of market exclusivity during which directly competitive similar products cannot normally be placed on the market.
The EMA grants orphan medicinal product designation based upon several criteria, including: the life threatening and debilitating nature of the condition; the medical plausibility of the proposed orphan indication; a prevalence in Europe of less than five cases for each 10,000 of population; no satisfactory method of diagnosis, prevention or treatment exists or if such method exists the medicinal product will be of significant benefit to those affected by that condition.
Y-mAbs&rsquo; founder, Chairman and President, Thomas Gad said, &ldquo;We are very pleased that the COMP has issued a positive opinion for an orphan drug designation to 177Lu-omburtamab-DTPA which will give us a string of development incentives.&rdquo;
Dr. Claus Moller, Chief Executive Officer further notes, &ldquo;We believe that the orphan designation strengthens our opportunity to bring 177Lu-omburtamab-DTPA to patients who desperately need alternative methods of treatment. Further, the designation marks a substantial milestone in Y-mAbs&rsquo; expansion into European development.&rdquo;
Researchers at MSK developed omburtamab, which is exclusively licensed by MSK to Y-mAbs. As a result of this licensing arrangement, MSK has institutional financial interests in the product.

YMAB

Y-mAbs Reports European Medicines Agency's Committee For Orphan Medicinal Products Recommended Granting Orphan Medicinal Product Designation In EU For Medulloblastoma Treatment

<ul>
<li>Adial Pharmaceuticals Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adil#NASDAQ">ADIL</a>) has received notice from the FDA that its request for Fast Track Designation for AD04 in Alcohol Use Disorder&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/06/g21714535/adial-pharmaceuticals-provides-regulatory-and-development-update" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">has been denied at this time</a>.&nbsp;</li>
<li>The FDA stated that the Company has not yet demonstrated that the product shows potential, and the agency asked for additional information regarding how AD04 might compare to other therapies.</li>
<li>Based on this feedback, Adial will review the additional requirements and data requested by the FDA for a Fast Track Designation.</li>
<li>The FDA&#39;s Fast Track is a process designed to facilitate development and expedite the regulatory review of drugs that treat serious conditions and address unmet medical needs with the purpose of getting important drugs to patients earlier.</li>
<li>AD04 is undergoing a Phase 3 ONWARD trial. The primary endpoint of efficacy is the change from baseline in the monthly number of heavy drinking days during the last eight weeks of the 24-week treatment period.</li>
<li>Price Action: ADIL shares are up 3.17% at $2.60 during the premarket session on the last check Friday.</li>
</ul>

Biotech

Penny Stocks

Health Care

ADIL

FDA Denies Adial Pharma's Fast Track Request For AD04 in Alcohol Use Disorder

Each day, Benzinga takes a look back at a notable market-related moment that occurred on this date.
What Happened?&nbsp;On this day in 1974, Texas Instruments Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/txn#NASDAQ">TXN</a>) received a patent for its hand-held aluminum calculator.
Where The Market Was: The Dow closed at 828.85. The S&amp;P 500 traded at around 88.98.
What Else Was Going On In The World?&nbsp;In 1974, the U.S. inflation rate ballooned to 11.3%. The 3-million-year-old remains of hominid &ldquo;Lucy&rdquo; were discovered in Ethiopia, the oldest known remains of a human ancestor ever discovered at the time. The average price of a new house was $34,900.
TI&rsquo;s Patented Hand-Held Calculator: TI engineers Jack Kilby, Jerry Merryman and James Van Tassel were granted the patent for TI&rsquo;s new hand-held calculator in June of 1974. The model was made of aluminum and weighed 2 pounds 13 ounces. The calculator could perform addition, subtraction multiplication and division, and TI initially priced the device starting at around $85.
<img alt="sr-50_early_ti_calculator.agr_.jpg" src="https://www.benzinga.com/files/images/2018/June/25/sr-50_early_ti_calculator.agr_.jpg" style="height:526px; width:300px" />
The SR-50 was Texas Instruments first scientific pocket calculator (1974) (<a href="https://commons.wikimedia.org/wiki/File:SR-50_early_TI_calculator.agr.jpg">ArnoldReinhold, Wikimedia</a>)
Kilby has initially nicknamed the prototype for the calculator &ldquo;Cal Tech,&rdquo; and its output was generated on a paper tape. Prior to &ldquo;mini&rdquo; calculators such as these, electronic calculators had been large heavy desktop machines containing hundreds of transistors and several circuit boards.
Kilby was best known for his invention of the monolithic integrated circuit, which sparked the $219 billion global integrated circuit market. Kilby won the <a href="http://www.ti.com/corp/docs/kilbyctr/jackstclair.shtml">Nobel Prize</a> for his work in 2000.

Education

Tech

This Day In Market History: Texas Instruments Patents Hand-Held Calculator

Surge Energy US Holdings Company (&quot;Surge Energy&quot; or the &quot;Company&quot;) announces it will partner with U.S. Well Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USWS#NASDAQ">USWS</a>) (&quot;USWS&quot;) on a field trial using USWS&#39; all-electric Clean Fleet&reg;. This project represents Surge&#39;s first well completions using all-electric hydraulic fracturing technology.
&quot;The utilization of Surge&#39;s electrical infrastructure for fracking is the latest example of Surge&#39;s commitment to sustainability through GHG emissions reduction,&quot; stated&nbsp;Linhua Guan, Surge&#39;s CEO. &quot;We are excited to be partnering with USWS on this project based on both companies&#39; shared commitment to reduce emissions through the use of innovation.&quot;
&nbsp;&quot;U.S. Well Services is pleased to be partnering with Surge Energy,&quot; commented&nbsp;Joel Broussard, USWS&#39; President and CEO. &quot;Surge is a leading Permian Basin E&amp;P operator and has consistently proven their commitment to reducing the emissions intensity of their operations through the use of advanced fracturing technology.&nbsp;Surge is an ideal customer for USWS given its dedication to electrifying the oilfield, as evidenced by their investments in infrastructure that could ultimately enable zero-emissions well completions using grid power. We are excited to deploy our Clean Fleet for Surge and demonstrate the fuel cost savings and emissions reduction potential of the technology during this upcoming field trial.&nbsp;We hope to build upon our relationship with Surge and leverage our intellectual property and expertise to help them explore future opportunities.&quot;

USWS

Surge Energy America Announces Electric Frack Fleet Field Trial With US Well Services; Financial Terms Not Disclosed

Exclusives

AMPE

EXCLUSIVE: Ampio Pharmaceuticals Announces Patient Randomization And Dosing In AP-019 Phase II Study Of Inhaled Ampion In COVID-19 Respiratory Distress

Baird analyst Jonathan Komp maintains Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Outperform and raises the price target from $150 to $192.

Baird Maintains Outperform on Nike, Raises Price Target to $192

<ul>
<li>Tonix Pharmaceuticals Holding Corp&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tnxp#NASDAQ">TNXP</a>)&nbsp;<a class="editor-rtfLink" href="https://www.sec.gov/Archives/edgar/data/1430306/000138713121006844/ex99-01.htm" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">said in a regulatory filing</a>&nbsp;that plans are underway to construct a commercial-scale manufacturing site to develop and manufacture vaccines, including its experimental COVID-19 shot, TNX-1800.</li>
<li>The Montana facility intended to develop and manufacture Tonix&rsquo;s vaccine candidates will be a &ldquo;public/private sector collaboration between Ravalli County and Tonix Pharmaceuticals that will bring more high-tech bioscience jobs to the Bitterroot Valley,&rdquo; the company said.</li>
<li>Early this week, Tonix announced its plans to develop the fibromyalgia candidate, TNX-102 SL,&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/21/06/21641402/tonix-pharma-to-test-its-fibromyalgia-candidate-in-long-covid-syndrome" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">as a potential treatment for Long COVID Syndrome</a>.</li>
<li>Price Action:&nbsp;TNXP shares are up 13.6% at $1.25 during the premarket session on the last check Friday.</li>
</ul>

Small Cap

TNXP

Tonix Pharma Stock Moving Higher On Plans For Vaccine Manufacturing Facility In Bitterroot Valley

Baird analyst David Tarantino maintains Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Outperform and raises the price target from $152 to $160.

Baird Maintains Outperform on Darden Restaurants, Raises Price Target to $160

<ul>
<li>The European Commission (EC) has approved&nbsp;Sanofi SA&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sny#NASDAQ">SNY</a>) and&nbsp;Regeneron Pharmaceuticals Inc&#39;s&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/regn#NASDAQ">REGN</a>) Libtayo (cemiplimab) for two additional indications - basal cell carcinoma (BCC) and&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/06/g21717683/sanofi-libtayo-cemiplimab-approved-by-the-european-commission-for-first-line-treatment-of-patients" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">non-small cell lung cancer with over 50% PD-L1 expression</a>.</li>
<li><a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/06/g21717863/sanofi-libtayo-cemiplimab-approved-by-the-european-commission-as-the-first-immunotherapy-indicated" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">BCC (skin cancer) approval covers</a>&nbsp;adults with locally advanced or metastatic disease who have progressed on or are intolerant to a hedgehog pathway inhibitor.</li>
<li>Concurrently, the Commission approved Libtayo for the first-line treatment of adult patients with advanced non-small-cell lung cancer whose tumor cells have over 50% PD-L1 expression and no EGFR, ALK, or ROS1 aberrations.&nbsp;</li>
<li>In 2019, Libtayo was approved by the EC as the first treatment for adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.</li>
<li>Libtayo is now approved by the European Commission for three advanced cancers.</li>
<li>Price Action: REGN shares closed at $544.4, and SNY closed at $52.32 on Friday.</li>
</ul>

REGN

Sanofi - Regeneron's Immunotherapy Scores European Approval For Skin And Lung Cancer Settings

Reneo Pharmaceuticals Shares Will Open For Quote At 11 a.m. EDT, Expected To Open For Trade After 11:10 a.m. EDT; IPO Priced At $15/Share

Reneo Pharmaceuticals Shares Open For Trade At $15.30; IPO Priced At $15/Share

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours:

<h3>Scaling The Peaks</h3>

(Biotech Stocks Hitting 52-week Highs April 12)

<ul>
	<li>180 Life Sciences Corp. (NASDAQ:<a class="ticker" href="/stock/ATNF#NASDAQ">ATNF</a>) (<a href="https://www.benzinga.com/news/21/04/20581755/why-ikena-oncology-evelo-biosciences-and-180-life-sciences-are-rallying-today">moved </a> on insider buying)</li>
	<li>Celcuity Inc. (NASDAQ:<a class="ticker" href="/stock/CELC#NASDAQ">CELC</a>)</li>
	<li>Fortress Biotech, Inc. (NASDAQ:<a class="ticker" href="/stock/FBIO#NASDAQ">FBIO</a>)</li>
	<li>Gain Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/GANX#NASDAQ">GANX</a>)</li>
	<li>Medtronic plc (NYSE:<a class="ticker" href="/stock/MDT#NYSE">MDT</a>)</li>
	<li>Merit Medical Systems, Inc. (NASDAQ:<a class="ticker" href="/stock/MMSI#NASDAQ">MMSI</a>)</li>
	<li>MiMedx Group, Inc. (NASDAQ:<a class="ticker" href="/stock/MDXG#NASDAQ">MDXG</a>)</li>
</ul>

<h3>Down In The Dumps</h3>

(Biotech Stocks Hitting 52-week Lows April 12)

<ul>
	<li>4D Molecular Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/FDMT#NASDAQ">FDMT</a>)</li>
	<li>ACADIA Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="/stock/ACAD#NASDAQ">ACAD</a>)</li>
	<li>Achilles Therapeutics plc (NASDAQ:<a class="ticker" href="/stock/ACHL#NASDAQ">ACHL</a>) (reacted to presentation at the American Association of Cancer Research annual meeting)</li>
	<li>Acutus Medical, Inc. (NASDAQ:<a class="ticker" href="/stock/AFIB#NASDAQ">AFIB</a>)</li>
	<li>Adverum Biotechnologies, Inc. (NASDAQ:<a class="ticker" href="/stock/ADVM#NASDAQ">ADVM</a>)</li>
	<li>Adagene Inc. (NASDAQ:<a class="ticker" href="/stock/ADAG#NASDAQ">ADAG</a>)</li>
	<li>Aprea Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/APRE#NASDAQ">APRE</a>)</li>
	<li>Assembly Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/ASMB#NASDAQ">ASMB</a>)</li>
	<li>Axsome Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/AXSM#NASDAQ">AXSM</a>)</li>
	<li>Bellerophon Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/BLPH#NASDAQ">BLPH</a>)</li>
	<li>Biophytis SA (NASDAQ:<a class="ticker" href="/stock/BPTS#NASDAQ">BPTS</a>)</li>
	<li>Bolt Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/BOLT#NASDAQ">BOLT</a>)</li>
	<li>Calithera Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/CALA#NASDAQ">CALA</a>)</li>
	<li>Checkmate Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/CMPI#NASDAQ">CMPI</a>) (reacted to AACR presentation)</li>
	<li>Coherus BioSciences, Inc. (NASDAQ:<a class="ticker" href="/stock/CHRS#NASDAQ">CHRS</a>)</li>
	<li>Concert Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/CNCE#NASDAQ">CNCE</a>)</li>
	<li>ContraFect Corporation (NASAQ: CFRX)</li>
	<li>Decibel Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/DBTX#NASDAQ">DBTX</a>)</li>
	<li>Design Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/DSGN#NASDAQ">DSGN</a>)</li>
	<li>Fusion Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="/stock/FUSN#NASDAQ">FUSN</a>)</li>
	<li>Idera Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/IDRA#NASDAQ">IDRA</a>)</li>
	<li>Immunocore Holdings plc (NASDAQ:<a class="ticker" href="/stock/IMCR#NASDAQ">IMCR</a>)</li>
	<li>IMARA Inc. (NASDAQ:<a class="ticker" href="/stock/IMRA#NASDAQ">IMRA</a>)</li>
	<li>Instil Bio, Inc. (NASDAQ:<a class="ticker" href="/stock/TIL#NASDAQ">TIL</a>) (moved on AACR presentation)</li>
	<li>Ionis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/IONS#NASDAQ">IONS</a>)</li>
	<li>Kronos Bio, Inc. (NASDAQ:<a class="ticker" href="/stock/KRON#NASDAQ">KRON</a>) (reacted to preclinical data presented at AACR meeting)</li>
	<li>Longboard Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/LBPH#NASDAQ">LBPH</a>)</li>
	<li>MediciNova, Inc. (NASDAQ:<a class="ticker" href="/stock/MNOV#NASDAQ">MNOV</a>)</li>
	<li>Metacrine, Inc. (NASDAQ:<a class="ticker" href="/stock/MTCR#NASDAQ">MTCR</a>)</li>
	<li>Millendo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/MLND#NASDAQ">MLND</a>)</li>
	<li>NeuBase Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/NBSE#NASDAQ">NBSE</a>)</li>
	<li>Qualigen Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/QLGN#NASDAQ">QLGN</a>) (<a href=" https://www.benzinga.com/general/biotech/21/04/20573957/why-is-qualigen-stock-trading-lower-today">withdrew </a> emergency use authorization application for COVID-19 diagnostic test)</li>
	<li>Reata Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/RETA#NASDAQ">RETA</a>)</li>
	<li>Reneo Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/RPHM#NASDAQ">RPHM</a>) (went public&nbsp;Friday)</li>
	<li>Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="/stock/RVPH#NASDAQ">RVPH</a>)</li>
	<li>Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/SRPT#NASDAQ">SRPT</a>)</li>
	<li>Sigilon Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/SGTX#NASDAQ">SGTX</a>)</li>
	<li>Soleno Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/SLNO#NASDAQ">SLNO</a>)</li>
	<li>Syros Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/SYRS#NASDAQ">SYRS</a>)</li>
	<li>Titan Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/TTNP#NASDAQ">TTNP</a>)</li>
	<li>VectivBio Holding AG (NASDAQ:<a class="ticker" href="/stock/VECT#NASDAQ">VECT</a>) (went public Friday)</li>
	<li>Y-mAbs Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/YMAB#NASDAQ">YMAB</a>) (presented clinical data at AACR meeting)</li>
</ul>

<h3>Stocks In Focus</h3>

<h3>Amarin Names Insider Karim Mikhail As CEO</h3>

Amarin Corporation plc (NASDAQ:<a class="ticker" href="/stock/AMRN#NASDAQ">AMRN</a>) announced that CEO John Thero has informed the board of directors of his plan to retire from the position of CEO&nbsp;effective Aug. 1. He will also step down from the board at that time.

The board has appointed Karim Mikhail, Amarin&#39;s senior SVP and head of commercial for Europe, to succeed Thero as the company&#39;s next president and CEO and as a board member. Thero will continue to provide his guidance and expertise to the company in an advisory capacity through the end of 2021, the company said.

The stock was down 2.74% premarket at $5.68.&nbsp;

<h3>Johnson &amp; Johnson&#39;s Vaccine Use Paused By FDA</h3>

The Food and Drug Administration and the Centers for Disease Control and Prevention are <a href="https://www.benzinga.com/general/biotech/21/04/20595814/fda-recommends-pause-in-use-of-johnson-johnsons-covid-19-vaccine-on-blood-clot-concerns">recommending a pause</a> in the use of Johnson &amp; Johnson&#39;s (NYSE:<a class="ticker" href="/stock/JNJ#NYSE">JNJ</a>) COVID-19 vaccine due to reports of a rare type of blood clots.

The stock was down 2.68% at $157.30 in premarket trading Tuesday.

<h3>Roche Snags&nbsp;FDA Approval For Self-Injectable, Prefilled Syringe For Asthma Drug</h3>

Roche Holding AG (OTC:<a class="ticker" href="/stock/RHHBY#OTC">RHHBY</a>) said the U.S. Food and Drug Administration has approved its supplemental Biologics License Application for Xolair, a prefilled syringe for self-injection across all approved U.S. indications.

Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E for the treatment of moderate to severe persistent allergic asthma, chronic idiopathic urticaria and nasal polyps.

<h3>Immunocore Presents Positive Phase 3 Data For Eye Cancer Drug</h3>

Immunocore presented at the AACR annual meeting with&nbsp;data from a Phase 3 trial comparing tebentafusp with investigator&#39;s choice, in first-line metastatic uveal melanoma, showing tebentafusp demonstrated a statistically significant and clinically meaningful improvement in overall survival as a first-line treatment for the condition.&nbsp;Treatment-related adverse events were manageable and consistent with the proposed mechanism.

The stock rose 3.57% to $33.37 in after-hours trading.

<h3>Burning Rock Biotech&#39;s Liquid Biopsy Assay Performs Strongly In&nbsp;Midstage Study</h3>

Burning Rock Biotech Limited (NASDAQ:<a class="ticker" href="/stock/BNR#NASDAQ">BNR</a>) announced the publication in Nature Biotechnology of results from a FDA-led Sequencing Quality Control Phase 2 study.

The data shows the liquid biopsy assay has achieved strong performance. For samples at a 25ng input, Burning Rock&#39;s assay was the most accurate assay, with roughly equivalent sensitivity but superior precision compared to other assays, the company said.&nbsp;

Related Link: <a href="https://www.benzinga.com/general/biotech/21/04/20567086/the-week-ahead-in-biotech-april-11-17-avenue-therapeutics-fda-decision-and-conference-presentatio"> The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight </a>

<h3>Lilly-Innovent Presents Positive Late-Stage Tyvyt Data&nbsp;In Second-Line Lung Cancer Setting</h3>

Eli Lilly and Company (NYSE:<a class="ticker" href="/stock/LLY#NYSE">LLY</a>) and Hong Kong-based partner Innovent Biologics presented at the AACR annual meeting with results of the Phase 3 ORIENT-3 study evaluating Tyvyt versus the&nbsp; chemotherapy medication docetaxel as a second-line treatment for advanced or metastatic squamous non-small cell lung cancer.

The presentation shows that Tyvyt demonstrated a statistically significant improvement in overall survival compared to docetaxel, meeting the pre-specified primary endpoint.

The median progression-free survival as assessed by investigators was 4.3&nbsp;months versus 2.79 months, and the confirmed objective response rate was 25.5% versus 2.2%, respectively. Safety was consistent with previous studies of Tyvyt and no new safety signals were identified.

<h3>Tiziana to Seek Nasdaq Listing For Former Subsidiary Accustem</h3>

Tiziana Life Sciences PLC (NASDAQ:<a class="ticker" href="/stock/TLSA#NASDAQ">TLSA</a>) announced that its former subsidiary&nbsp;Accustem Sciences Limited&nbsp;intends to file a listing application with the Nasdaq after completion of the distribution of shares in Accustem to Tiziana shareholders.

The Nasdaq listing venue is more appropriate to the nature of Accustem&#39;s business in the view of Accustem&#39;s board.&nbsp;

The stock was trading 0.69% higher at $706.80 premarket Tuesday.

<h3>Offerings</h3>

Liquidia Corporation (NASDAQ:<a class="ticker" href="/stock/LQDA#NASDAQ">LQDA</a>) said it has entered into a common stock purchase agreement with certain institutional, accredited investors for the private placement of 8.626 million shares of common stock at a purchase price of $2.52 per share. The private placement is expected to close Tuesday and yield gross proceeds of approximately $21.7 million.

<h3>On The Radar</h3>

<h3>Clinical Readouts</h3>

Affimed N.V. (NASDAQ:<a class="ticker" href="/stock/AFMD#NASDAQ">AFMD</a>) will present at the AACR annual meeting initial clinical data from an investigator-sponsored Phase 1 study evaluating cord blood-derived natural killercells pre-complexed with Affimed&#39;s innate cell engager AFM13. The company&#39;s shares reacted positively Friday&nbsp;when the company released a statement elaborating on data from the study.

Auris Medical Holding Ltd. (NASDAQ:<a class="ticker" href="/stock/EARS#NASDAQ">EARS</a>) is scheduled to provide a business update on its pre-clinical asset AM-301. AM-301 is being evaluated for protection against airborne viruses and allergens.&nbsp;

Related Link: <a href="https://www.benzinga.com/general/biotech/21/04/20405937/attention-biotech-investors-mark-your-calendar-for-april-pdufa-dates"> Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates </a>

The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours.

<h3>Scaling The Peaks</h3>

(Biotech Stocks Hitting 52-week Highs April 13)

<ul>
	<li>Bio-Techne Corporation (NASDAQ:<a class="ticker" href="/stock/TECH#NASDAQ">TECH</a>)</li>
	<li>Celcuity Inc. (NASDAQ:<a class="ticker" href="/stock/CELC#NASDAQ">CELC</a>)</li>
	<li>Medpace Holdings, Inc. (NASDAQ:<a class="ticker" href="/stock/MEDP#NASDAQ">MEDP</a>)</li>
	<li>Medtronic plc (NYSE:<a class="ticker" href="/stock/MDT#NYSE">MDT</a>)</li>
	<li>MiMedx Group, Inc. (NASDAQ:<a class="ticker" href="/stock/MDXG#NASDAQ">MDXG</a>)</li>
	<li>Natus Medical Incorporated (NASDAQ:<a class="ticker" href="/stock/NTUS#NASDAQ">NTUS</a>)</li>
	<li>NovoCure Limited (NASDAQ:<a class="ticker" href="/stock/NVCR#NASDAQ">NVCR</a>) (<a href="https://www.benzinga.com/intraday-update/21/04/20604757/12-health-care-stocks-moving-in-tuesdays-intraday-session">reacted </a> to positive independent Data Monitoring Committee review of pivotal Phase 3 study data for lung cancer treatment candidate)</li>
	<li>Theratechnologies Inc. (NASDAQ:<a class="ticker" href="/stock/THTX#NASDAQ">THTX</a>)</li>
	<li>Zymeworks Inc. (NYSE:<a class="ticker" href="/stock/ZYME#NYSE">ZYME</a>)</li>
</ul>

<h3>Down In The Dumps</h3>

(Biotech Stocks Hitting 52-week Lows April 13)

<ul>
	<li>Acutus Medical, Inc. (NASDAQ:<a class="ticker" href="/stock/AFIB#NASDAQ">AFIB</a>) (announced FDA clearance for AcQCross family of universal transseptal crossing devices)</li>
	<li>Adverum Biotechnologies, Inc. (NASDAQ:<a class="ticker" href="/stock/ADVM#NASDAQ">ADVM</a>)</li>
	<li>Aprea Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/APRE#NASDAQ">APRE</a>)</li>
	<li>Assembly Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/ASMB#NASDAQ">ASMB</a>)</li>
	<li>Athenex, Inc. (NASDAQ:<a class="ticker" href="/stock/ATNX#NASDAQ">ATNX</a>)</li>
	<li>Atreca, Inc. (NASDAQ:<a class="ticker" href="/stock/BCEL#NASDAQ">BCEL</a>)</li>
	<li>Avidity Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/RNA#NASDAQ">RNA</a>)</li>
	<li>Axsome Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/AXSM#NASDAQ">AXSM</a>)</li>
	<li>Calithera Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/CALA#NASDAQ">CALA</a>)</li>
	<li>Celyad Oncology SA (NASDAQ:<a class="ticker" href="/stock/CYAD#NASDAQ">CYAD</a>)</li>
	<li>Checkmate Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/CMPI#NASDAQ">CMPI</a>)</li>
	<li>Coherus BioSciences, Inc. (NASDAQ:<a class="ticker" href="/stock/CHRS#NASDAQ">CHRS</a>)</li>
	<li>ContraFect Corporation (NASAQ: CFRX)</li>
	<li>Decibel Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/DBTX#NASDAQ">DBTX</a>)</li>
	<li>Design Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/DSGN#NASDAQ">DSGN</a>)</li>
	<li>Evofem Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/EVFM#NASDAQ">EVFM</a>)</li>
	<li>Homology Medicines, Inc. (NASDAQ:<a class="ticker" href="/stock/FIXX#NASDAQ">FIXX</a>)</li>
	<li>Idera Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/IDRA#NASDAQ">IDRA</a>)</li>
	<li>IMARA Inc. (NASDAQ:<a class="ticker" href="/stock/IMRA#NASDAQ">IMRA</a>)</li>
	<li>Ionis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/IONS#NASDAQ">IONS</a>)</li>
	<li>iRhythm Technologies, Inc. (NASDAQ:<a class="ticker" href="/stock/IRTC#NASDAQ">IRTC</a>) (announced revenue impact from recently published Medicare reimbursement rate by Novitas)</li>
	<li>Karyopharm Therapeutics Inc. (NASDAQ:<a class="ticker" href="/stock/KPTI#NASDAQ">KPTI</a>)</li>
	<li>Kronos Bio, Inc. (NASDAQ:<a class="ticker" href="/stock/KRON#NASDAQ">KRON</a>)</li>
	<li>Lixte Biotechnology Holdings, Inc. (NASDAQ:<a class="ticker" href="/stock/LIXT#NASDAQ">LIXT</a>)</li>
	<li>MediciNova, Inc. (NASDAQ:<a class="ticker" href="/stock/MNOV#NASDAQ">MNOV</a>)</li>
	<li>Metacrine, Inc. (NASDAQ:<a class="ticker" href="/stock/MTCR#NASDAQ">MTCR</a>)</li>
	<li>Millendo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/MLND#NASDAQ">MLND</a>)</li>
	<li>Nabriva Therapeutics plc (NASDAQ:<a class="ticker" href="/stock/NBRV#NASDAQ">NBRV</a>)</li>
	<li>NeuBase Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/NBSE#NASDAQ">NBSE</a>)</li>
	<li>Osmotica Pharmaceuticals plc (NASDAQ:<a class="ticker" href="/stock/OSMT#NASDAQ">OSMT</a>)</li>
	<li>PainReform Ltd. (NASDAQ:<a class="ticker" href="/stock/PRFX#NASDAQ">PRFX</a>)</li>
	<li>Pulmatrix, Inc. (NASDAQ:<a class="ticker" href="/stock/PULM#NASDAQ">PULM</a>) (reacted to termination of license agreement for Johnson &amp; Johnson (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jnj#NYSE">JNJ</a>))</li>
	<li>Qualigen Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/QLGN#NASDAQ">QLGN</a>)</li>
	<li>Reata Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/RETA#NASDAQ">RETA</a>)</li>
	<li>Relay Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/RLAY#NASDAQ">RLAY</a>)</li>
	<li>Reneo Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/RPHM#NASDAQ">RPHM</a>) (IPOed Friday)</li>
	<li>Repro Med Systems, Inc. (NASDAQ:<a class="ticker" href="/stock/KRMD#NASDAQ">KRMD</a>)</li>
	<li>Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="/stock/RVPH#NASDAQ">RVPH</a>)</li>
	<li>Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/SRPT#NASDAQ">SRPT</a>)</li>
	<li>Syros Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/SYRS#NASDAQ">SYRS</a>)</li>
	<li>Titan Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/TTNP#NASDAQ">TTNP</a>)</li>
	<li>VectivBio Holding AG (NASDAQ:<a class="ticker" href="/stock/VECT#NASDAQ">VECT</a>) (IPOed Friday)</li>
	<li>Voyager Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/VYGR#NASDAQ">VYGR</a>)</li>
	<li>Y-mAbs Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/YMAB#NASDAQ">YMAB</a>)</li>
</ul>

<h3>Stocks In Focus</h3>

<h3>Novavax Announces Departure of CFO, Executive Appointments</h3>

Novavax, Inc. (NASDAQ:<a class="ticker" href="/stock/NASDAQ#NASDAQ">NASDAQ</a>) announced CFO Greg Covino will step down for personal reasons and will take on a new role as executive adviser to the company. John Trizzino, EVP, chief commercial officer and chief business officer, will assume the CFO role on an interim basis while a search is underway for a replacement.

The company also announced the promotion of Gale Smith to the role of SVP, Discovery and Pre-Clinical Research and chief scientist, and the appointment of biopharma industry veteran Troy Morgan as SVP, chief compliance officer.

The stock was down 1.37% to $192 in after-hours trading.

<h3>Flexion Expects Q1 Revenues to Be Roughly In Line With Estimates Despite COVID Impact</h3>

Flexion Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/FLXN#NASDAQ">FLXN</a>) announced preliminary first-quarter revenues, comprising solely Zilretta sales, of $24.6 million, roughly in line with the $25.23 million consensus estimate. Zilretta is an FDA-approved medication indicated to treat osteoarthritis of the knee. The company expects full-year revenues of $120 million to $130 million. Analysts, on average, estimate net sales of $137.42 million.

The stock rose 5.96% to $9.96 in after-hours trading.

<h3>Zai Labs Announces Cancer Collaboration Deal With Preclinical Biotech RubrYc</h3>

Zai Lab Limited (NASDAQ:<a class="ticker" href="/stock/ZLAB#NASDAQ">ZLAB</a>) announced an R&amp;D collaboration and license option agreement with preclinical biotherapeutics company RubrYc, under which both companies will collaborate to identify product candidates using RubrYc&#39;s Discovery Engine, which leverages machine learning and structural data to identify antibodies that bind to subdominant epitopes and exhibit differentiated activity for an undisclosed oncology target.

On exercising of the licensing option, Zai Lab will have exclusive global rights to develop and commercialize product(s) of the collaboration. RubrYc will receive an upfront payment and is eligible to receive future research, development and commercialization milestones on a per candidate basis, along with royalties on worldwide net sales of each product.

Related Link: <a href=" https://www.benzinga.com/general/biotech/21/04/20405937/attention-biotech-investors-mark-your-calendar-for-april-pdufa-dates"> Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates </a>

<h3>Longboard Spikes On No Major News</h3>

Longboard Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/LBPH#NASDAQ">LBPH</a>), which IPOed recently, was found rallying ahead of the closing of the offering.

The stock surged up 33.22% to $15.80 in after-hours trading.

<h3>Gilead&#39;s Antibody-drug Conjugate Approved For Urothelial Cancer</h3>

Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="/stock/GILD#NASDAQ">GILD</a>) said the U.S. Food and Drug Administration has granted accelerated approval of Trodelvy, an antibody-drug conjugate, for use in adult patients with locally advanced or metastatic urothelial cancer, who have previously received a platinum-containing chemotherapy and immunotherapy. The Trodelvy U.S. prescribing Information has a boxed warning for severe or life-threatening neutropenia and severe diarrhea.

<h3>Merck, TILT to Collaborate For Phase 1 Study of Oncolytic Virus-Keytruda Combo For Ovarian Cancer</h3>

TILT Biotherapeutics, clinical-stage biotech developing cancer immunotherapeutics, announced a clinical trial collaboration agreement with Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="/stock/MRK#NYSE">MRK</a>) to evaluate TILT&#39;s adenoviral cancer immunotherapy TILT-123, a dual cytokine armed oncolytic adenovirus, in combination with Keytruda, in a Phase I dose escalation trial in platinum-resistant or refractory ovarian cancer.

<h3>J&amp;J to Delay COVID-19 Vaccine Rollout and Trials In Europe Following U.S. Regulatory Decision to Pause</h3>

In response to the <a href="https://www.benzinga.com/news/21/04/20606157/can-nio-stock-go-from-40-to-400-in-18-months">pause recommendation</a> for the use of its COVID-19 vaccine, J&amp;J said it is reviewing the cases with European health authorities in a bid to proactively delay the rollout of its vaccine in Europe and pause vaccinations in all its COVID-19 vaccine clinical trials.

&quot;We have been working closely with medical experts and health authorities, and we strongly support the open communication of this information to healthcare professionals and the public,&quot; the company added.

<h3>Moderna Announces Positive Preclinical Data For COVID-19 Variant-specific Vaccine Candidates</h3>

Moderna, Inc. (NASDAQ:<a class="ticker" href="/stock/MRNA#NASDAQ">MRNA</a>) announced new results from a preclinical study of the its COVID-19 variant-specific vaccine candidates showed that the variant-specific booster vaccine candidates - mRNA-1273.351 and mRNA-1273.211 - increase neutralizing titers against SARS-CoV-2 variants of concern.

The company also said it remains on track to deliver the second 100 million doses to the U.S. government by end of May 2021 followed by another 100 million additional doses by end of July 2021.

The stock was higher by 1.92% to $152.59 in the after-hours trading.

<h3>Lilly Out-licenses Rights to Parkinson&#39;s Disease Antibody Therapy In Greater China Region</h3>

SciNeuro Pharma announced an exclusive license agreement with Eli Lilly and Company (NYSE:<a class="ticker" href="/stock/LLY#NYSE">LLY</a>) for the development and commercialization of alpha-synuclein targeted antibody therapies for the treatment of Parkinson&#39;s disease, in Greater China, which includes mainland China, Hong Kong, Macau and Taiwan.

Under the terms of the agreement, SciNeuro has obtained an exclusive license to alpha-synuclein targeted antibodies developed by Lilly, within Greater China. Lilly will receive an upfront cash payment, in addition to downstream milestones and royalties on products developed and commercialized by SciNeuro. Lilly retains all rights outside Greater China.

The stock was up 0.37% to $183.20 in premarket trading Wednesday.

<h3>Offerings</h3>

Satsuma Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/STSA#NASDAQ">STSA</a>) said selling shareholders may offer and sell up to 14.085 million shares of our common stock from time to time in one or more offerings.

The stock slid 9.85% to $4.85 in after-hours trading.

Earnings

Pre-Market Outlook

The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead

<ul>
	<li>Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs.</li>
	<li>Even with a new earnings season underway, insiders were still making notable share purchases.</li>
	<li>Some of those insiders made return trips to the buy window, and a couple of chief executives were among the buyers too.</li>
</ul>

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So <a href="https://www.benzinga.com/news/insider-trades" target="_blank">insider buying</a> can be an encouraging signal for potential investors, particularly when there is uncertainty in the markets or the markets are near all-time highs.

Note that, with the new earnings reporting season underway, many insiders are prohibited from buying or selling shares. Here are some of the most noteworthy insider purchases that were reported in the past week.

Evergy Inc (NYSE:<a class="ticker" href="/stock/EVRG#NYSE">EVRG</a>) saw a director indirectly acquire more than $113.17 million worth of shares mid-week. That was nearly 2.27 million shares of this Kansas City-based electric utility purchased at $49.87 apiece. The stock popped 4% last week and was last seen trading at $63.29 per share.

San Diego-based Reneo Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="/stock/RPHM#NASDAQ">RPHM</a>) had two directors and two beneficial owners pick up more than 1.73 million shares altogether at the initial public offering price of $15&nbsp;apiece. That cost almost $26&nbsp;million. However, the stock ended the week&#39;s trading at $13&nbsp;per share.

Stonemor Inc (NYSE:<a class="ticker" href="/stock/STON#NYSE">STON</a>) saw a director indirectly purchase more than 5.52 million shares last week at $2.20 apiece. That added up to around $12.15 million and lifted his stake in this funeral home and cemetery operator to over 88.63 million shares. The total float is more than 106 million shares, and the stock ended the week trading at $2.18 a share.

The more than 121,200 GMS Inc (NYSE:<a class="ticker" href="/stock/GMS#NYSE">GMS</a>) shares that a 10% owner indirectly purchased last week had prices ranging from $42.19 to $44.20 apiece. These transactions added up to over $5.26 million. Note that this owner also <a href="https://www.benzinga.com/news/21/04/20472797/last-weeks-notable-insider-buys-pennymac-financial-republic-services-and-more" target="_blank">bought 115,000 shares</a> of the building products provider at the end of March.

Chief Executive Officer Patrick Soon-Shiong bought shares of NantHealth Inc (NASDAQ:<a class="ticker" href="/stock/NH#NASDAQ">NH</a>) last week. The almost 1.69 million shares that were indirectly acquired, at $2.96 apiece, totaled about $5&nbsp;million. While this insider buy <a href="https://www.benzinga.com/general/biotech/21/04/20657868/the-daily-biotech-pulse-precision-biosciences-regains-rights-to-car-t-candidates-cfo-changes-2-ip" target="_blank">helped lift shares</a> of the healthcare IT company, they still ended the week at $2.58.

Late last week, Tattooed Chef Inc (NASDAQ:<a class="ticker" href="/stock/TTCF#NASDAQ">TTCF</a>) had a director pay $10&nbsp;a share in a privately negotiated transaction. The more than 250,000 shares cost that director $2.50 million. Note that CEO Salvatore Galletti also parted with 800,000 shares at the same price. The most recent share price was $18.71.

A 10% owner of Molecular Templates Inc (NASDAQ:<a class="ticker" href="/stock/MTEM#NASDAQ">MTEM</a>) returned to the buy window in the past week. That owner added 200,000 more shares to its stake, bringing the total to more than 9.35 million shares. At prices that ranged from $7.80 to $8.38 per share, the latest transactions added up to more than $2.43 million. Note that this owner <a href="https://www.benzinga.com/news/21/04/20567977/the-past-weeks-notable-insider-buys-included-biotechs-public-offerings-a-spac-and-more" target="_blank">bought 700,000 shares</a> in the prior week.

CEO Albert Bolles and three other insiders at Landec Corporation (NASDAQ:<a class="ticker" href="/stock/LNDC#NASDAQ">LNDC</a>) stepped up to the buy window after its quarterly report. Altogether, they picked up almost 265,600 shares for around $10.01 to $10.98 apiece. These purchases added up to more than $2.67 million. The share price on Friday&#39;s close was $11.20.

And a Nuvation Bio Inc (NASDAQ:<a class="ticker" href="/stock/NUVB#NASDAQ">NUVB</a>) director indirectly acquired 164,500 shares last week. At prices of $9.48 to $10.28 a share, this cost that director more than $1.58 million, and it lifted the stake to over 6.99 million shares. Note that this director bought 300,000 shares in the previous week.

See also: <a href="https://www.benzinga.com/news/21/04/20633609/richard-branson-sheds-virgin-galactic-stake-by-150m" target="_blank">Richard Branson Sheds Virgin Galactic Stake By $150M</a>

Note that some smaller amount of insider buying at bioharma Liquidia Corp (NASDAQ:<a class="ticker" href="/stock/LQDA#NASDAQ">LQDA</a>), Merrimack Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="/stock/MACK#NASDAQ">MACK</a>), property insurer Old Republic International Corporation (NYSE:<a class="ticker" href="/stock/ORI#NYSE">ORI</a>), Texas Pacific Land Corp (NYSE:<a class="ticker" href="/stock/TPL#NYSE">TPL</a>) and utility York Water Co (NASDAQ:<a class="ticker" href="/stock/YORW#NASDAQ">YORW</a>) was reported in the past week as well.

At the time of this writing, the author had no position in the mentioned equities.

Keep up with all the latest breaking news and trading ideas by following Benzinga on <a href="https://twitter.com/Benzinga" target="_blank">Twitter</a>.

Photo by&nbsp;<a href="https://unsplash.com/@austindistel?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Austin Distel</a>&nbsp;on&nbsp;<a href="https://unsplash.com/s/photos/equity?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Unsplash</a>.

Insider Trades

Last Week's Notable Insider Buys Included Evergy, StoneMor, Tattooed Chef And More

Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Reneo Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPHM#NASDAQ">RPHM</a>) with a Overweight rating and announces Price Target of $45.

Initiation

Piper Sandler Initiates Coverage On Reneo Pharmaceuticals with Overweight Rating, Announces Price Target of $45

Jefferies analyst Eun Yang initiates coverage on Reneo Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPHM#NASDAQ">RPHM</a>) with a Buy rating and announces Price Target of $24.

Jefferies Initiates Coverage On Reneo Pharmaceuticals with Buy Rating, Announces Price Target of $24

SVB Leerink analyst Joseph Schwartz initiates coverage on Reneo Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPHM#NASDAQ">RPHM</a>) with a Outperform rating and announces Price Target of $25.

SVB Leerink Initiates Coverage On Reneo Pharmaceuticals with Outperform Rating, Announces Price Target of $25

&nbsp;

<h2>Upgrades</h2>

<ul>
	<li>For Genuine Parts Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NYSE">GPC</a>), Goldman Sachs upgraded the previous rating of Sell to Neutral. In the first quarter, Genuine Parts showed an EPS of $1.50, compared to $0.92 from the year-ago quarter. At the moment, the stock has a 52-week-high of $128.46 and a 52-week-low of $67.12. Genuine Parts closed at $127.19 at the end of the last trading period.</li>
	<li>For Fox Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>), Rosenblatt upgraded the previous rating of Sell to Neutral. In the second quarter, Fox showed an EPS of $0.16, compared to $0.10 from the year-ago quarter. The current stock performance of Fox shows a 52-week-high of $44.80 and a 52-week-low of $23.57. Moreover, at the end of the last trading period, the closing price was at $36.61.</li>
	<li>According to Wedbush, the prior rating for Shift Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFT#NASDAQ">SFT</a>) was changed from Underperform to Neutral. In the fourth quarter, Shift Technologies earned $0.07. The stock has a 52-week-high of $12.34 and a 52-week-low of $6.40. At the end of the last trading period, Shift Technologies closed at $8.60.</li>
	<li>Needham upgraded the previous rating for Cirrus Logic Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRUS#NASDAQ">CRUS</a>) from Hold to Buy. Cirrus Logic earned $0.66 in the fourth quarter, compared to $0.68 in the year-ago quarter. The current stock performance of Cirrus Logic shows a 52-week-high of $103.25 and a 52-week-low of $55.30. Moreover, at the end of the last trading period, the closing price was at $73.00.</li>
	<li>According to UBS, the prior rating for Quest Diagnostics Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) was changed from Neutral to Buy. In the first quarter, Quest Diagnostics showed an EPS of $3.76, compared to $0.94 from the year-ago quarter. The stock has a 52-week-high of $134.75 and a 52-week-low of $103.26. At the end of the last trading period, Quest Diagnostics closed at $132.69.</li>
	<li>According to Credit Suisse, the prior rating for Cogent Communications Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCOI#NASDAQ">CCOI</a>) was changed from Neutral to Outperform. In the first quarter, Cogent Comms Hldgs showed an EPS of $0.41, compared to $0.20 from the year-ago quarter. At the moment, the stock has a 52-week-high of $90.96 and a 52-week-low of $53.20. Cogent Comms Hldgs closed at $76.09 at the end of the last trading period.</li>
	<li>BFor Nutanix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>), JP Morgan upgraded the previous rating of Neutral to Overweight. In the second quarter, Nutanix showed an EPS of $0.37, compared to $0.60 from the year-ago quarter. The current stock performance of Nutanix shows a 52-week-high of $35.58 and a 52-week-low of $17.29. Moreover, at the end of the last trading period, the closing price was at $26.54.</li>
	<li>According to Bernstein, the prior rating for Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) was changed from Underperform to Market Perform. In the first quarter, Boeing showed an EPS of $1.53, compared to $1.70 from the year-ago quarter. The stock has a 52-week-high of $278.57 and a 52-week-low of $113.89. At the end of the last trading period, Boeing closed at $235.28.</li>
	<li>Baird upgraded the previous rating for ON Semiconductor Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) from Neutral to Outperform. In the first quarter, ON Semiconductor showed an EPS of $0.35, compared to $0.10 from the year-ago quarter. At the moment, the stock has a 52-week-high of $44.59 and a 52-week-low of $13.48. ON Semiconductor closed at $37.57 at the end of the last trading period.</li>
	<li>Needham upgraded the previous rating for Ceragon Networks Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNT#NASDAQ">CRNT</a>) from Hold to Buy. In the first quarter, Ceragon Networks showed an EPS of $0.01, compared to $0.08 from the year-ago quarter. The stock has a 52-week-high of $6.90 and a 52-week-low of $1.95. At the end of the last trading period, Ceragon Networks closed at $3.33.</li>
	<li>According to Atlantic Equities, the prior rating for W.W. Grainger Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWW#NYSE">GWW</a>) was changed from Underweight to Neutral. For the first quarter, W.W. Grainger had an EPS of $4.48, compared to year-ago quarter EPS of $4.24. The current stock performance of W.W. Grainger shows a 52-week-high of $452.82 and a 52-week-low of $263.27. Moreover, at the end of the last trading period, the closing price was at $443.97.</li>
	<li>For Advance Auto Parts Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>), Goldman Sachs upgraded the previous rating of Sell to Buy. For the fourth quarter, Advance Auto Parts had an EPS of $1.87, compared to year-ago quarter EPS of $1.64. The current stock performance of Advance Auto Parts shows a 52-week-high of $203.62 and a 52-week-low of $115.00. Moreover, at the end of the last trading period, the closing price was at $202.28.</li>
</ul>

<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings upgrades.</a>

&nbsp;

<h2>Downgrades</h2>

<ul>
	<li>According to Northcoast Research, the prior rating for Domino&#39;s Pizza Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) was changed from Buy to Neutral. For the first quarter, Domino&#39;s Pizza had an EPS of $3.00, compared to year-ago quarter EPS of $3.07. At the moment, the stock has a 52-week-high of $435.67 and a 52-week-low of $319.71. Domino&#39;s Pizza closed at $433.01 at the end of the last trading period.</li>
	<li>UBS downgraded the previous rating for Teva Pharmaceutical Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) from Buy to Neutral. In the first quarter, Teva Pharmaceutical Indus showed an EPS of $0.63, compared to $0.76 from the year-ago quarter. At the moment, the stock has a 52-week-high of $13.30 and a 52-week-low of $8.44. Teva Pharmaceutical Indus closed at $10.82 at the end of the last trading period.</li>
	<li>According to Credit Suisse, the prior rating for Commercial Metals Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMC#NYSE">CMC</a>) was changed from Outperform to Neutral. Commercial Metals earned $0.66 in the second quarter, compared to $0.53 in the year-ago quarter. At the moment, the stock has a 52-week-high of $32.43 and a 52-week-low of $13.72. Commercial Metals closed at $30.41 at the end of the last trading period.</li>
	<li>According to Raymond James, the prior rating for Crown Castle International Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) was changed from Outperform to Market Perform. Crown Castle Intl earned $1.71 in the first quarter, compared to $1.42 in the year-ago quarter. The stock has a 52-week-high of $189.59 and a 52-week-low of $146.15. At the end of the last trading period, Crown Castle Intl closed at $187.83.</li>
	<li>According to Goldman Sachs, the prior rating for The Kroger Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) was changed from Neutral to Sell. In the fourth quarter, Kroger showed an EPS of $0.81, compared to $0.57 from the year-ago quarter. The current stock performance of Kroger shows a 52-week-high of $42.99 and a 52-week-low of $30.35. Moreover, at the end of the last trading period, the closing price was at $37.37.</li>
	<li>For Albertsons Companies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>), Goldman Sachs downgraded the previous rating of Buy to Neutral. In the fourth quarter, Albertsons Companies earned $0.60. The stock has a 52-week-high of $20.89 and a 52-week-low of $12.91. At the end of the last trading period, Albertsons Companies closed at $18.85.</li>
	<li>According to William Blair, the prior rating for Lucira Health Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LHDX#NASDAQ">LHDX</a>) was changed from Outperform to Market Perform. At the moment, the stock has a 52-week-high of $37.98 and a 52-week-low of $5.94. Lucira Health closed at $5.98 at the end of the last trading period.</li>
	<li>Baird downgraded the previous rating for Bank of America Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) from Outperform to Neutral. For the first quarter, Bank of America had an EPS of $0.86, compared to year-ago quarter EPS of $0.40. The stock has a 52-week-high of $41.13 and a 52-week-low of $20.10. At the end of the last trading period, Bank of America closed at $40.53.</li>
	<li>JP Morgan downgraded the previous rating for Ashland Global Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASH#NYSE">ASH</a>) from Neutral to Underweight. Ashland Global Holdings earned $1.05 in the second quarter, compared to $0.84 in the year-ago quarter. The stock has a 52-week-high of $95.20 and a 52-week-low of $55.41. At the end of the last trading period, Ashland Global Holdings closed at $86.70.</li>
	<li>According to Keybanc, the prior rating for Dollar General Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) was changed from Overweight to Sector Weight. Dollar General earned $2.62 in the fourth quarter, compared to $2.10 in the year-ago quarter. The current stock performance of Dollar General shows a 52-week-high of $225.25 and a 52-week-low of $172.66. Moreover, at the end of the last trading period, the closing price was at $216.41.</li>
</ul>

<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings downgrades.</a>

&nbsp;

<h2>Initiations</h2>

<ul>
	<li>With an Overweight rating, JP Morgan initiated coverage on Roblox Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>). The price target seems to have been set at $85.00 for Roblox. The current stock performance of Roblox shows a 52-week-high of $83.41 and a 52-week-low of $60.50. Moreover, at the end of the last trading period, the closing price was at $71.04.</li>
	<li>JP Morgan initiated coverage on Piedmont Lithium Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLL#NASDAQ">PLL</a>) with an Overweight rating. The price target for Piedmont Lithium is set to $86.00. In the third quarter, Piedmont Lithium earned $0.92. The current stock performance of Piedmont Lithium shows a 52-week-high of $88.97 and a 52-week-low of $5.45. Moreover, at the end of the last trading period, the closing price was at $68.32.</li>
	<li>With a Buy rating, Alliance Global Partners initiated coverage on Pluristem Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTI#NASDAQ">PSTI</a>). The price target seems to have been set at $12.50 for Pluristem Therapeutics. Pluristem Therapeutics earned $0.49 in the second quarter, compared to $0.40 in the year-ago quarter. At the moment, the stock has a 52-week-high of $12.15 and a 52-week-low of $4.03. Pluristem Therapeutics closed at $4.24 at the end of the last trading period.</li>
	<li>With a Buy rating, Citigroup initiated coverage on Dada Nexus Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DADA#NASDAQ">DADA</a>). The price target seems to have been set at $36.00 for Dada Nexus. Interestingly, in the fourth quarter, Dada Nexus&#39;s EPS was $0.09. The stock has a 52-week-high of $61.27 and a 52-week-low of $14.60. At the end of the last trading period, Dada Nexus closed at $24.03.</li>
	<li>With an Outperform rating, SVB Leerink initiated coverage on Reneo Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPHM#NASDAQ">RPHM</a>). The price target seems to have been set at $25.00 for Reneo Pharmaceuticals. At the moment, the stock has a 52-week-high of $17.18 and a 52-week-low of $11.63. Reneo Pharmaceuticals closed at $14.50 at the end of the last trading period.</li>
	<li>With an Outperform rating, Credit Suisse initiated coverage on VectivBio Holding AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VECT#NASDAQ">VECT</a>). The price target seems to have been set at $24.00 for VectivBio Holding. The stock has a 52-week-high of $37.70 and a 52-week-low of $14.86. At the end of the last trading period, VectivBio Holding closed at $15.21.</li>
	<li>Guggenheim initiated coverage on Infrastructure and Energy Alternatives Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IEA#NASDAQ">IEA</a>) with a Buy rating. The price target for Infrastructure and Energy is set to $17.00. In the fourth quarter, Infrastructure and Energy showed an EPS of $0.10, compared to $0.31 from the year-ago quarter. The current stock performance of Infrastructure and Energy shows a 52-week-high of $24.13 and a 52-week-low of $1.63. Moreover, at the end of the last trading period, the closing price was at $13.51.</li>
	<li>Cantor Fitzgerald initiated coverage on Metromile Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MILE#NASDAQ">MILE</a>) with an Overweight rating. The price target for Metromile is set to $13.00. Metromile earned $1.56 in the fourth quarter. The stock has a 52-week-high of $20.39 and a 52-week-low of $7.14. At the end of the last trading period, Metromile closed at $8.96.</li>
	<li>With an Outperform rating, RBC Capital initiated coverage on Intellia Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>). The price target seems to have been set at $110.00 for Intellia Therapeutics. For the fourth quarter, Intellia Therapeutics had an EPS of $0.69, compared to year-ago quarter EPS of $0.57. At the moment, the stock has a 52-week-high of $92.00 and a 52-week-low of $12.32. Intellia Therapeutics closed at $73.80 at the end of the last trading period.</li>
	<li>RBC Capital initiated coverage on Sangamo Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) with an Outperform rating. The price target for Sangamo Therapeutics is set to $22.00. Sangamo Therapeutics earned No EPS Value in the first quarter, compared to $0.37 in the year-ago quarter. At the moment, the stock has a 52-week-high of $19.43 and a 52-week-low of $7.65. Sangamo Therapeutics closed at $11.63 at the end of the last trading period.</li>
	<li>Stephens &amp; Co. initiated coverage on Contango Oil &amp; Gas Co (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MCF#AMEX">MCF</a>) with an Overweight rating. The price target for Contango Oil &amp; Gas is set to $5.00. In the fourth quarter, Contango Oil &amp; Gas showed an EPS of $0.16, compared to $1.32 from the year-ago quarter. The current stock performance of Contango Oil &amp; Gas shows a 52-week-high of $5.56 and a 52-week-low of $1.09. Moreover, at the end of the last trading period, the closing price was at $3.84.</li>
	<li>With a Sector Perform rating, RBC Capital initiated coverage on Beam Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>). The price target seems to have been set at $85.00 for Beam Therapeutics. In the fourth quarter, Beam Therapeutics earned $1.69. The stock has a 52-week-high of $126.90 and a 52-week-low of $14.80. At the end of the last trading period, Beam Therapeutics closed at $75.19.</li>
	<li>With a Sector Perform rating, RBC Capital initiated coverage on Editas Medicine Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>). The price target seems to have been set at $40.00 for Editas Medicine. In the fourth quarter, Editas Medicine showed an EPS of $1.00, compared to $0.74 from the year-ago quarter. The current stock performance of Editas Medicine shows a 52-week-high of $99.95 and a 52-week-low of $21.41. Moreover, at the end of the last trading period, the closing price was at $35.59.</li>
	<li>Oppenheimer initiated coverage on Trinity Capital Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIN#NASDAQ">TRIN</a>) with an Outperform rating. The price target for Trinity Capital is set to $15.00. Interestingly, in the fourth quarter, Trinity Capital&#39;s EPS was $0.29. At the moment, the stock has a 52-week-high of $15.99 and a 52-week-low of $13.46. Trinity Capital closed at $14.59 at the end of the last trading period.</li>
	<li>William Blair initiated coverage on MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) with a Market Outperform rating. For the first quarter, MicroStrategy had an EPS of $1.54, compared to year-ago quarter EPS of $0.39. At the moment, the stock has a 52-week-high of $1315.00 and a 52-week-low of $109.64. MicroStrategy closed at $635.62 at the end of the last trading period.</li>
</ul>

<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings initiations.</a>

Upgrades

Downgrades

Intraday Update

Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2021

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours:

<h3>Scaling The Peaks</h3>

(Biotech Stocks Hitting 52-week Highs May 12)

<ul>
	<li>Alexion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXN#NASDAQ">ALXN</a>)</li>
	<li>Curis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>)</li>
	<li>HOOKIPA Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOK#NASDAQ">HOOK</a>) (announced first-quarter results)</li>
	<li>Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>)</li>
	<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)</li>
	<li>Vaccitech plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VACC#NASDAQ">VACC</a>)</li>
</ul>

<h3>Down In The Dumps</h3>

(Biotech Stocks Hitting 52-week Lows May 12)

<ul>
	<li>4D Molecular Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>)</li>
	<li>Akoya Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>)</li>
	<li>Bellerophon Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLPH#NASDAQ">BLPH</a>)</li>
	<li>Bolt Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>)</li>
	<li>Co-Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>)</li>
	<li>Concert Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNCE#NASDAQ">CNCE</a>)</li>
	<li>Connect Biopharma Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTB#NASDAQ">CNTB</a>)</li>
	<li>Dyadic International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>)</li>
	<li>Eloxx Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELOX#NASDAQ">ELOX</a>)</li>
	<li>Finch Therapeutics Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNCH#NASDAQ">FNCH</a>)</li>
	<li>Galecto, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLTO#NASDAQ">GLTO</a>)</li>
	<li>Gemini Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMTX#NASDAQ">GMTX</a>)</li>
	<li>InflaRx N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFRX#NASDAQ">IFRX</a>) (announced&nbsp;first-quarter results and a midstage readout for its investigational therapy for inflammation of blood vessels)</li>
	<li>Instil Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>)</li>
	<li>Kiromic BioPharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRBP#NASDAQ">KRBP</a>)</li>
	<li>Larimar Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>)</li>
	<li>LogicBio Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>)</li>
	<li>Longeveron Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>)</li>
	<li>NuCana plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>)</li>
	<li>Nymox Pharmaceutical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYMX#NASDAQ">NYMX</a>)</li>
	<li>Odonate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODT#NASDAQ">ODT</a>)</li>
	<li>Opthea Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPT#NASDAQ">OPT</a>)</li>
	<li>Orgenesis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGS#NASDAQ">ORGS</a>)</li>
	<li>Orphazyme A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORPH#NASDAQ">ORPH</a>)</li>
	<li>PMV Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMVP#NASDAQ">PMVP</a>)</li>
	<li>PolyPid Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPD#NASDAQ">PYPD</a>) (announced&nbsp;first-quarter results)</li>
	<li>Praxis Precision Medicines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>) (<a href="https://www.benzinga.com/general/biotech/21/05/21078722/the-daily-biotech-pulse-minerva-inflarx-report-positive-data-readouts-lucira-covid-19-test-kit-av">reacted </a> to a common stock offering)</li>
	<li>Reneo Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPHM#NASDAQ">RPHM</a>)</li>
	<li>Scopus BioPharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCPS#NASDAQ">SCPS</a>)</li>
	<li>Sensei Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>)</li>
	<li>Soligenix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>)</li>
	<li>Talaris Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TALS#NASDAQ">TALS</a>)</li>
	<li>Talis Biomedical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLIS#NASDAQ">TLIS</a>) (announced&nbsp;first-quarter results)</li>
	<li>VectivBio Holding AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VECT#NASDAQ">VECT</a>)</li>
	<li>Vallon Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLON#NASDAQ">VLON</a>)</li>
	<li>Vor Biopharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>)</li>
	<li>Zealand Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZEAL#NASDAQ">ZEAL</a>) (announced first-quarter results)</li>
</ul>

<h3>Stocks In Focus</h3>

<h3>Novo Nordisk&#39;s Diabetes Drug Found To Improve Quality Of Life In People With Obesity In Late-Stage Study</h3>

Novo Nordisk announced new results from the STEP Phase 3a clinical trial program that demonstrate&nbsp;potential benefits beyond weight loss for people with obesity being treated with semaglutide 2.4 mg.

Following the 68-week treatment period with once-weekly semaglutide, more than half of participants had improved quality of life scores, indicating better physical function and improved psychological wellbeing.

<h3>Celyad&#39;s Cell Therapy Candidate Shows Promise In Early Stage Blood Cancer Study</h3>

Celyad Oncology SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYAD#NASDAQ">CYAD</a>) said Phase 1 data from the IMMUNICY-1 study of CYAD-211, a non-gene edited allogenic CAR T candidate, showed initial clinical activity, with one confirmed partial response in a low dose, in treating relapsed/refractory multiple myeloma.

There were no Grade 3 or greater treatment-related adverse events nor evidence of Graft-versus-Host disease reported from the completed first dose level.

The company said an abstract highlighting the data has been accepted for e-poster presentation at the upcoming European Hematology Association Virtual Congress 2021.

The stock was trading 19.21% higher premarket Thursday at $6.33.&nbsp;

<h3>4D Molecular Presents Positive Data From Animal Study Of Gene Therapy Candidate In Retinal Disorders</h3>

4D Molecular announced a presentation at the ASGCT Meeting of new preclinical data from non-human primate studies of 4D-150, a dual transgene, intravitreal gene therapy inhibiting four distinct VEGF family members for the treatment of wet age-related macular degeneration and diabetic macular edema.

The study demonstrated significant efficacy in the laser-induced choroidal neovascularization model, including complete suppression of CNV lesions at the lowest dose, the company said. High anti-VEGF levels within the NHP eye were observed, with no evidence of uveitis or retinal abnormalities, according to 4D Molecular.&nbsp;

<h3>Merck&#39;s Keytruda Found Effective, Safe In Neoadjuvant/Adjuvant Setting In Breast Cancer</h3>

Merck (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) announced positive results from the pivotal neoadjuvant/adjuvant Phase 3 KEYNOTE-522 trial investigating Keytruda&nbsp;in combination with chemotherapy as pre-operative treatment, and then continuing as a single agent treatment after surgery.

The KEYNOTE-522 trial met its dual primary endpoint of event-free survival for the treatment of patients with high-risk, early stage triple-negative breast cancer. The safety profile of Keytruda in this trial was consistent with that observed in previously reported studies and no new safety signals were identified.

Related Link: <a href="https://www.benzinga.com/general/biotech/21/05/21024458/the-week-ahead-in-biotech-may-9-15-heron-apellis-fda-decisions-presentations-and-earnings"> The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings </a>

<h3>AzurRx&#39;s MS1819 Combo Therapy Aces Midstage Trial In Cystic Fibrosis Patients With Pancreatic Insufficiency</h3>

AzurRx BioPharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZRX#NASDAQ">AZRX</a>) announced positive interim data from the first 18 out of 20 patients in its Phase 2 trial evaluating MS1819 in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy, for the treatment of severe exocrine pancreatic insufficiency in patients with cystic fibrosis.

The shares were adding 8.98% to 79.51 cents in premarket trading Thursday.

<h3>Qiagen Gets FDA Emergency Use Authorization For Portable Digital Antibody COVID-19 Test</h3>

QIAGEN N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) said it has received <a href="https://www.benzinga.com/government/20/04/15759780/what-is-fda-emergency-use-authorization"> emergency use authorization </a> from the FDA for the fast, easy-to-use QIAreach anti-SARS-CoV-2 Total Test.

The authorization allows health care professionals gain access to portable rapid testing device that can monitor immune status in relation to COVID-19. The eHub digital device, according to the company, can handle eight tests at once, all working independently of each other, and can process up to 32 samples per hour. It can eventually be used simultaneously with the antigen test

<h3>Earnings</h3>

Curis reported first-quarter revenues of $2.19 million, down from $2.71 million in the year-ago period. The net loss narrowed from 28 cents to 11 cents.

The company also announced the release of abstract accepted for presentation at the EHA meeting, with interim data from the Phase 1/2 study of CA-4948 in patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome consistent with previously announced findings, including marrow blast reductions observed at all tested doses in eight of nine&nbsp;evaluable patients.

The stock plunged 13.95% to $45 in after-hours trading.

Profound Medical Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROF#NASDAQ">PROF</a>) reported a decline in its first-quarter revenues from $1.16 million in 2020 to $711,000 in 2021. The loss per share widened from 21 cents

The stock slipped 11.7% to $16.70 in after-hours trading.

Evoke Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) reported net sales of about $90,000 and the net loss was $2.6 million, or 8 cents&nbsp;per share, compared to a net loss of approximately $1.8 million, or 7 cents per share for the first quarter of 2020. Analysts expected a smaller loss of 6 cents per share.

In after-hours trading, the stock plunged 21.71% to $1.19.

<h3>On The Radar</h3>

<h3>Clinical Readouts</h3>

Fate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>) is scheduled to release interim Phase 1 data from its FT516 and FT538 programs at an investor event scheduled for Thursday. Both are iPSC-derived NK cell therapeutic candidates being evaluated for the treatment of relapsed/refractory acute myeloid leukemia.

Sio Gene Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIOX#NASDAQ">SIOX</a>) will present at the American Society of Gene and Cell Therapy meeting with&nbsp;preliminary results from the Phase 1/2 trial of AXO-AAV-GM1 for the treatment of GM1 gangliosidosis. The company will also present efficacy, safety, and tolerability data six&nbsp;months post-administration from the second cohort in open-label dose evaluation study SUNRISE-PD of AXO-Lenti-PD gene therapy for Parkinson&#39;s disease.

<h3>Earnings</h3>

<ul>
	<li>Galmed Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) (before the market open)</li>
	<li>Synlogic, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYBX#NASDAQ">SYBX</a>) (before the market open)</li>
	<li>Wave Life Sciences Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) (before the market open)</li>
	<li>UroGen Pharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) (before the market open)</li>
	<li>Selecta Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SELB#NASDAQ">SELB</a>) (before the market open)</li>
	<li>PDS Biotechnology Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) (before the market open)</li>
	<li>Haemonetics Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>) (before the market open)</li>
	<li>Osmotica Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSMT#NASDAQ">OSMT</a>) (after the close)</li>
	<li>ImmuCell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCC#NASDAQ">ICCC</a>) (after the close)</li>
	<li>Achieve Life Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHV#NASDAQ">ACHV</a>) (after the close)</li>
	<li>Dar&eacute; Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DARE#NASDAQ">DARE</a>) (after the close)</li>
	<li>BioLife Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) (after the close)</li>
	<li>Atea Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVIR#NASDAQ">AVIR</a>) (after the close)</li>
	<li>Anavex Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) (after the close)</li>
	<li>AbCellera Biologics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABCL#NASDAQ">ABCL</a>) (after the close)</li>
	<li>aTyr Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFE#NASDAQ">LIFE</a>) (after the close)</li>
	<li>Aptinyx Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTX#NASDAQ">APTX</a>) (after the close)</li>
	<li>Brickell Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBI#NASDAQ">BBI</a>) (after the close)</li>
	<li>Bionano Genomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) (after the close)</li>
	<li>Co-Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) (after the close)</li>
	<li>Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) (after the close)</li>
	<li>Dyadic International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) (after the close)</li>
	<li>DermTech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMTK#NASDAQ">DMTK</a>) (after the close)</li>
	<li>Lineage Cell Therapeutics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LCTX#NYSE">LCTX</a>) (after the close)</li>
	<li>HTG Molecular Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTGM#NASDAQ">HTGM</a>) (after the close)</li>
	<li>Eledon Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELDN#NASDAQ">ELDN</a>) (after the close)</li>
	<li>Eton Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETON#NASDAQ">ETON</a>) (after the close)</li>
	<li>ThermoGenesis Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THMO#NASDAQ">THMO</a>) (after the close)</li>
	<li>ProPhase Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) (after the close)</li>
	<li>Spectrum Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPPI#NASDAQ">SPPI</a>) (after the close)</li>
	<li>TFF Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) (after the close)</li>
	<li>Regulus Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) (after the close)</li>
	<li>Infinity Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INFI#NASDAQ">INFI</a>) (after the close)</li>
	<li>Marinus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) (after the close)</li>
	<li>PolarityTE, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTE#NASDAQ">PTE</a>) (after the close)</li>
</ul>

Related Link: <a href="https://www.benzinga.com/general/biotech/21/05/20890405/attention-biotech-investors-mark-your-calendar-for-may-pdufa-dates">Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates </a>

The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use

<h3>Gainers</h3>

<ul>
	<li>AMC Entertainment Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) shares surged 23.7% to close at $12.77.</li>
	<li>Moxian, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOXC#NASDAQ">MOXC</a>) jumped 23.6% to close at $9.52.</li>
	<li>Repro Med Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRMD#NASDAQ">KRMD</a>) gained 18.5% to settle at $4.17 following strong quarterly sales.</li>
	<li>Lianluo Smart Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LLIT#NASDAQ">LLIT</a>) jumped 18.4% to close at $7.15 after dipping 38% on Wednesday.</li>
	<li>Ramaco Resources, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/METC#NASDAQ">METC</a>) jumped 16.8% to close at $4.87 after the company reported an increase in quarterly earnings.</li>
	<li>Comstock Holding Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHCI#NASDAQ">CHCI</a>) rose 16.5% to close at $7.19 after gaining 8% on Wednesday.</li>
	<li>Flux Power Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLUX#NASDAQ">FLUX</a>) jumped 16.4% to close at $8.95 after the company reported better-than-expected Q3 results.</li>
	<li>Reliance Global Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELI#NASDAQ">RELI</a>) climbed 16.3% to close at $3.43 on Thursday after the company said it has acquired a premier health insurance agency, J.P. Kush and Associates, Inc.</li>
	<li>MultiPlan Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLN#NYSE">MPLN</a>) rose 16.3% to close at $7.15 after the company reported better-than-expected Q1 results.</li>
	<li>A-Mark Precious Metals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRK#NASDAQ">AMRK</a>) rose 15.7% to close at $45.42 after the company reported a sharp rise in Q3 earnings.</li>
	<li>JanOne Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAN#NASDAQ">JAN</a>) gained 15.4% to close at $6.81.</li>
	<li>Sol-Gel Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLGL#NASDAQ">SLGL</a>) surged 15.2% to close at $11.45 after the company reported a narrower quarterly loss.</li>
	<li>InnSuites Hospitality Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHT#NYSE">IHT</a>) shares gained 14.2% to settle at $6.43 after dropping around 15% on Wednesday.</li>
	<li>Bridgford Foods Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRID#NASDAQ">BRID</a>) surged 14.2% to close at $20.10.</li>
	<li>Verso Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRS#NYSE">VRS</a>) jumped 13.9% to close at $17.09. Verso reported commencement of $55m modified Dutch auction tender offer for its class A common stock.</li>
	<li>Trinity Biotech plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) climbed 13.9% to close at $3.36.</li>
	<li>Fuel Tech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEK#NASDAQ">FTEK</a>) shares jumped 13.9% to close at $2.21 after the company reported upbeat results for its first quarter on Wednesday.</li>
	<li>Larimar Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>) rose 13.7% to close at $11.76. The company recently announced topline data from its Phase 1 multiple ascending dose trial evaluating CTI-1601 as a treatment for Friedreich&#39;s Ataxia (FA).</li>
	<li>Silvergate Capital Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SI#NYSE">SI</a>) shares jumped 13.7% to settle at $91.92 after Diem announced a partnership with the company to become the exclusive issuer of the Diem USD stablecoin.</li>
	<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) rose 13.6% to settle at $164.50.</li>
	<li>BRT Apartments Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRT#NYSE">BRT</a>) gained 13.5% to close at $18.27. BRT Apartments reported termination of public offering of common stock.</li>
	<li>Charah Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRA#NASDAQ">CHRA</a>) surged 13.4% to settle at $5.93 following Q1 results.</li>
	<li>Fossil Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOSL#NASDAQ">FOSL</a>) climbed 13.1% to close at $11.35 after the company reported better-than-expected Q1 sales results.</li>
	<li>Express, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXPR#NYSE">EXPR</a>) gained 13% to close at $3.22.</li>
	<li>Farmer Bros. Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARM#NASDAQ">FARM</a>) gained 12.3% to close at $9.84. Farmer Bros, last week, reported worse-than-expected Q3 results.</li>
	<li>Celsius Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) jumped 12.1% to settle at $51.70 after the company reported better-than-expected Q1 sales results.</li>
	<li>Quad/Graphics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QUAD#NYSE">QUAD</a>) gained 9.8% to close at $3.26.</li>
	<li>Gannett Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCI#NYSE">GCI</a>) climbed 9.7% to close at $4.87. The company, last week, reported a Q1 loss.</li>
	<li>Funko, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNKO#NASDAQ">FNKO</a>) climbed 9.6% to close at $23.24 after B of A Securities upgraded the stock from Underperform to Buy and raised the price from $12 to $30 per share.</li>
	<li>Applied UV, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUVI#NASDAQ">AUVI</a>) rose 8.9% to close at $7.73.</li>
	<li>Celyad Oncology SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYAD#NASDAQ">CYAD</a>) rose 8.1% to close at $5.74. Celyad Oncology said Phase 1 data from the IMMUNICY-1 study of CYAD-211, a non-gene edited allogenic CAR T candidate, showed initial clinical activity, with one confirmed partial response in a low dose, in treating relapsed/refractory multiple myeloma..</li>
	<li>Benitec Biopharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) rose 7.8% to settle at $4.69.</li>
	<li>Array Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) rose 7.4% to close at $14.45. Credit Suisse upgraded Array Technologies from Neutral to Outperform and lowered the price target from $42 to $31.</li>
	<li>Sonos, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONO#NASDAQ">SONO</a>) shares rose 7.4% to close at $33.83 after the company swung to a profit in the second quarter and raised FY21 sales guidance.</li>
	<li>Babcock &amp; Wilcox Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BW#NYSE">BW</a>) gained 6.5% to close at $7.76 following strong quarterly sales.</li>
</ul>

&nbsp;

&nbsp;

&nbsp;

 
<a href="https://www.benzinga.com/investing/best-penny-stocks/">Check out these big penny stock gainers and losers</a>

<h3>Losers</h3>

<ul>
	<li>Zovio Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVO#NASDAQ">ZVO</a>) shares tumbled 38.2% to close at $2.1450 on Thursday after the company reported wider-than-expected Q1 loss.</li>
	<li>ContextLogic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WISH#NASDAQ">WISH</a>) shares declined 29.3% to close at $8.11 after the company reported Q1 earnings results.</li>
	<li>Reneo Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPHM#NASDAQ">RPHM</a>) dropped 28.2% to settle at $8.01.</li>
	<li>Evoke Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares fell 25% to close at $1.14 after the company reported downbeat Q1 results.</li>
	<li>Braemar Hotels &amp; Resorts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHR#NYSE">BHR</a>) dropped 24.7% to close at $5.07.</li>
	<li>Dunxin Financial Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXF#NYSE">DXF</a>) fell 22.7% to settle at $1.60.</li>
	<li>Protagenic Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) fell 22% to close at $2.34.</li>
	<li>Obalon Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBLN#NASDAQ">OBLN</a>) dipped 22% to settle at $2.59. The company recently released Q1 results.</li>
	<li>Poshmark, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POSH#NASDAQ">POSH</a>) fell 21.8% to settle at $34.23 after the company reported Q1 results and issued Q2 guidance. Raymond James maintained Poshmark with an Outperform and lowered the price target from $68 to $58.</li>
	<li>cbdMD Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#NYSE">YCBD</a>) fell 21.8% to close at $2.69 after the company reported worse-than-expected Q2 results.</li>
	<li>Kubient, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KBNT#NASDAQ">KBNT</a>) dropped 21.6% to close at $4.05 after the company reported Q1 earnings results.</li>
	<li>American Well Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMWL#NYSE">AMWL</a>) fell 21.6% to close at $10.05 following downbeat quarterly sales.</li>
	<li>Fluor Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) dropped 20.4% to close at $18.93 as the company reported a convertible preferred stock offering.</li>
	<li>Frequency Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FREQ#NASDAQ">FREQ</a>) dipped 20.3% to settle at $8.05 following Q1 results.</li>
	<li>Curis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) shares fell 19.7% to close at $13.07 after the company reported worse-than-expected Q1 results.</li>
	<li>Flora Growth Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLGC#NASDAQ">FLGC</a>) dropped 19.6% to settle at $3.76. The company recently priced its 3.33 million share IPO at $5 per share.</li>
	<li>Second Sight Medical Products, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYES#NASDAQ">EYES</a>) dipped 19.4% to settle at $5.14.</li>
	<li>Sequential Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SQBG#NASDAQ">SQBG</a>) dropped 19.4% to close at $10.07. Sequential Brands Group recently received a waiver of existing defaults under its credit agreement through June 7th.</li>
	<li>Lucira Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LHDX#NASDAQ">LHDX</a>) fell 18.8% to close at $5.96. Lucira Health shares jumped 44% on Wednesday after the company said its Lucira CHECK IT COVID-19 test kit is now available on Amazon, Inc. in the US.</li>
	<li>Sio Gene Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIOX#NASDAQ">SIOX</a>) dipped 18.8% to close at $2.07 after the company announced new biomarker data from Phase 1/2 study of AXO-AAV-GM1, an adeno-associated viral vector (AAV)9-based gene therapy candidate for GM1 gangliosidosis.</li>
	<li>The9 Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCTY#NASDAQ">NCTY</a>) fell 18.4% to settle at $13.44.</li>
	<li>Turquoise Hill Resources Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRQ#NYSE">TRQ</a>) dropped 18.1% to close at $16.85 following Q1 results.</li>
	<li>180 Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) dropped 17.7% to settle at $6.85.</li>
	<li>MEI Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEIP#NASDAQ">MEIP</a>) fell 17.4% to close at $2.5950.</li>
	<li>Hycroft Mining Holding Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYMC#NASDAQ">HYMC</a>) dropped 17.1% to close at $3.50.</li>
	<li>InMed Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INM#NASDAQ">INM</a>) fell 16.8% to close at $2.81 after reporting a wider quarterly loss.</li>
	<li>Viracta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRX#NASDAQ">VIRX</a>) declined 16.6% to close at $7.66 following wider Q1 loss.</li>
	<li>Ebang International Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBON#NASDAQ">EBON</a>) fell 16.6% to settle at $2.41.</li>
	<li>908 Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASS#NASDAQ">MASS</a>) dipped 16.5% to close at $36.75 after reporting a loss for the first quarter.</li>
	<li>Eargo Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EAR#NASDAQ">EAR</a>) dropped 16.3% to settle at $32.66 after reporting a Q1 loss.</li>
	<li>Riot Blockchain, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) fell 16.2% to close at $22.23 after Tesla announced it will suspend accepting bitcoin as payment.</li>
	<li>Butterfly Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NASDAQ">BFLY</a>) dropped 15.8% to close at $9.45 following Q1 results.</li>
	<li>Anixa Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIX#NASDAQ">ANIX</a>) fell 15.8% to settle at $3.46.</li>
	<li>Avidity Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) dropped 15.7% to close at $19.62 after reporting a Q1 loss.</li>
	<li>SemiLEDs Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEDS#NASDAQ">LEDS</a>) dipped 15.5% to close at $6.25.</li>
	<li>Urogen Pharma Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) shares dropped 15.3% to close at $15.38 following downbeat quarterly sales.</li>
	<li>Mammoth Energy Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TUSK#NASDAQ">TUSK</a>) fell 15.2% to settle at $3.08.</li>
	<li>Bumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) fell 14.3% to close at $40.48 after reporting Q1 results.</li>
	<li>Dunxin Financial Holdings Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXF#NYSE">DXF</a>) dropped 14% to close at $2.09.</li>
	<li>Haemonetics Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>) dropped 13.4% to close at $51.81 after the company reported downbeat Q4 earnings.</li>
	<li>Marathon Digital Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) fell 11.9% to settle at $22.85 after declining 12% on Wednesday.</li>
	<li>Allied Healthcare Products, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHPI#NASDAQ">AHPI</a>) fell 10.8% to close at $3.78.</li>
</ul>

77 Biggest Movers From Yesterday

The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts

Reneo Pharmaceuticals Reports Q1 Net Income Per Share $(3.48) Down From $(2.20) YoY

&nbsp;

<h3>Gainers</h3>

<ul>
	<li>Kindred Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIN#NASDAQ">KIN</a>) shares increased by 24.08% to $6.75 during Thursday&#39;s regular session. Kindred Biosciences&#39;s stock is trading at a volume of 1.0 million shares as of 12:30 EST. This is 298.25% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $305.5 million.</li>
	<li>Sundial Growers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) shares rose 14.6% to $1.29. Trading volume for this security as of 12:30 EST is 695.9 million, which is 290.93% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $2.4 billion.</li>
	<li>Eloxx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELOX#NASDAQ">ELOX</a>) shares moved upwards by 12.89% to $1.79. Trading volume for this security as of 12:30 EST is 3.1 million, which is 346.44% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $154.7 million.</li>
	<li>Xeris Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XERS#NASDAQ">XERS</a>) stock increased by 7.87% to $3.5. Xeris Pharmaceuticals&#39;s stock is trading at a volume of 4.3 million shares as of 12:30 EST. This is 175.09% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $231.9 million.</li>
	<li>Immunovant (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMVT#NASDAQ">IMVT</a>) shares rose 7.25% to $10.64. Trading volume for this security as of 12:30 EST is 2.1 million, which is 162.08% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.0 billion. The company&#39;s, Q4 earnings came out 2 days ago.</li>
	<li>Biolase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOL#NASDAQ">BIOL</a>) shares rose 6.92% to $0.76. The current volume of 3.0 million shares is 49.14% of Biolase&#39;s average full-day volume over the last 100 days (last updated at 12:30 EST). The company&#39;s market cap stands at $114.7 million.</li>
</ul>

&nbsp;

&nbsp;

<h3>Losers</h3>

&nbsp;

<ul>
	<li>SELLAS Life Sciences Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLS#NASDAQ">SLS</a>) stock fell 14.65% to $10.76 during Thursday&#39;s regular session. The current volume of 938.6K shares is 163.47% of SELLAS Life Sciences Gr&#39;s average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $162.2 million.</li>
	<li>Reneo Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPHM#NASDAQ">RPHM</a>) stock declined by 13.49% to $9.25. Reneo Pharmaceuticals&#39;s stock is trading at a volume of 25.1K shares as of 12:30 EST. This is 18.34% of its average full-day volume over the last 100 days.</li>
	<li>PureTech Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTC#NASDAQ">PRTC</a>) shares declined by 12.95% to $50.11. PureTech Health&#39;s stock is trading at a volume of 3.1K shares as of 12:30 EST. This is 1317.72% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $1.4 billion.</li>
	<li>Replimune Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) stock declined by 12.23% to $31.82. The current volume of 521.5K shares is 142.98% of Replimune Group&#39;s average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $1.4 billion.</li>
	<li>Stealth BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MITO#NASDAQ">MITO</a>) stock fell 8.48% to $1.62. Stealth BioTherapeutics&#39;s stock is trading at a volume of 1.8 million shares as of 12:30 EST. This is 36.69% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $90.0 million.</li>
	<li>Decibel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBTX#NASDAQ">DBTX</a>) shares fell 7.25% to $7.81. As of 12:30 EST, Decibel Therapeutics&#39;s stock is trading at a volume of 56.2K, which is 43.7% of its average full-day volume over the last 100 days.</li>
</ul>

&nbsp;

&nbsp;

12 Health Care Stocks Moving In Thursday's Intraday Session

<h3>Gainers</h3>

<ul>
	<li>DLocal Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLO#NASDAQ">DLO</a>) shares jumped 54.2% to close at $32.39 on Thursday. DLocal raised around $92.6 million from the sale of 4.4 million shares in its IPO.</li>
	<li>GTT Communications, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTT#NYSE">GTT</a>) shares surged 39.6% to close at $3.49 on Thursday on abnormally-high volume. The company&rsquo;s stock also jumped over 57% on Wednesday.</li>
	<li>Energy Focus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFOI#NASDAQ">EFOI</a>) jumped 35.4% to close at $5.81. Energy Focus announced a partnership with threeUV to jointly market and distribute UV By Energy Focus products.</li>
	<li>The InterGroup Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTG#NASDAQ">INTG</a>) surged 30.1% to settle at $51.90.</li>
	<li>Community Bankers Trust Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESXB#NASDAQ">ESXB</a>) shares gained 29.4% to close at $11.90 after United Bankshares announced it will acquire Community Bankers Trust.</li>
	<li>Workhorse Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKHS#NASDAQ">WKHS</a>) surged 28.2% to close at $14.77 as retail trader interest increased as a result of the stock&#39;s high short interest. Workhorse Group shares also surged around 20% on Wednesday.</li>
	<li>Conn&#39;s, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CONN#NASDAQ">CONN</a>) gained 27.3% to settle at $30.57 after the company reported better-than-expected Q1 sales results.</li>
	<li>Kindred Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIN#NASDAQ">KIN</a>) climbed 23.7% to settle at $6.73. Kindred Biosciences recently reported results from pivotal efficacy study of parvovirus monoclonal antibody.</li>
	<li>PyroGenesis Canada Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYR#NASDAQ">PYR</a>) rose 23.4% to close at $6.34. PyroGenesis reported request for cost estimate from a major iron ore producer for thirty-six plasma torches.</li>
	<li>SemiLEDs Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEDS#NASDAQ">LEDS</a>) gained 23.3% to close at $15.10.</li>
	<li>Jiuzi Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZXN#NASDAQ">JZXN</a>) shares gained 20.3% to settle at $11.20. The company, last month, priced its upsized IPO of up to $5.2 million ordinary shares at $5 per share.</li>
	<li>Tellurian Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELL#NASDAQ">TELL</a>) jumped 19.2% to close at $5.16 after the company announced it signed a 10-year LNG agreement for 3 mtpa with Vitol.</li>
	<li>Xeris Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XERS#NASDAQ">XERS</a>) surged 18.8% to settle at $3.85.</li>
	<li>EuroDry Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDRY#NASDAQ">EDRY</a>) jumped 17.9% to close at $32.89.</li>
	<li>Ra Medical Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMED#NYSE">RMED</a>) gained 16.9% to close at $4.35. Ra Medical, last month, reported better-than-expected Q1 results.</li>
	<li>Vertex Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTNR#NASDAQ">VTNR</a>) gained 15.9% to close at $9.39 after declining around 6% on Wednesday.</li>
	<li>iPower Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPW#NASDAQ">IPW</a>) surged 15.1% to settle at $7.25.</li>
	<li>Tenneco Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEN#NYSE">TEN</a>) surged 15% to close at $21.13.</li>
	<li>Sigma Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGLB#NASDAQ">SGLB</a>) gained 14.8% to settle at $4.27.</li>
	<li>Recon Technology, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCON#NASDAQ">RCON</a>) jumped 14.7% to close at $13.68. Recon entered into share exchange agreement with Starry Blockchain Energy.</li>
	<li>Sundial Growers Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) rose 14.2% to close at $1.29 amid renewed interest from retail investors.</li>
	<li>Castor Maritime Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTRM#NASDAQ">CTRM</a>) rose 13.1% to close at $3.53 after the company swung to a profit in the first quarter.</li>
	<li>Nortech Systems Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSYS#NASDAQ">NSYS</a>) gained 12.8% to settle at $7.22. Nortech Systems announced a Cooperation and Project Funding agreement with Marp&eacute; Technologies and the BIRD Foundation.</li>
	<li>Clean Energy Fuels Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNE#NASDAQ">CLNE</a>) rose 12.2% to close at $9.12.</li>
	<li>1847 Goedeker Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOED#NYSE">GOED</a>) shares climbed 11.3% to close at $2.56. Sabby recently disclosed a 11% passive stake in 1847 Goedeker.</li>
	<li>Vascular Biogenics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBLT#NASDAQ">VBLT</a>) gained 10.5% to close at $2.64 after the company announced a primary endpoint amendment in the OVAL Phase 3 registration-enabling study of VB-111.</li>
	<li>Elastic NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) rose 10% to settle at $129.84 after the company reported better-than-expected Q4 results and issued strong sales guidance.</li>
	<li>Asensus Surgical, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASXC#NYSE">ASXC</a>) gained 8.9% to settle at $2.70.</li>
	<li>IGM Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGMS#NASDAQ">IGMS</a>) rose 8.7% to close at $87.94. The company highlighted expansion of IgM platform into infectious diseases.</li>
	<li>Salarius Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) rose 5.3% to close at $1.40 after gaining around 5% on Wednesday.</li>
</ul>

 
<a href="https://www.benzinga.com/investing/best-penny-stocks/">Check out these big penny stock gainers and losers</a>

<h3>Losers</h3>

<ul>
	<li>PetMed Express, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PETS#NASDAQ">PETS</a>) fell 28.3% to close at $33.01 after climbing 58% on Wednesday.</li>
	<li>Bed Bath &amp; Beyond Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBBY#NASDAQ">BBBY</a>) shares fell 27.8% to settle at $31.90 on Thursday after surging 62% on Wednesday. Bed Bath &amp; Beyond recently announced plans to launch three new Owned Brands this quarter.</li>
	<li>Tian Ruixiang Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIRX#NASDAQ">TIRX</a>) shares dipped 24.5% to close at $7.60 on Thursday after the company priced its 4.8 million unit follow-on offering at $7.50 per unit.</li>
	<li>Koss Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOSS#NASDAQ">KOSS</a>) dipped 24.3% to settle at $30.83. Koss shares jumped 69% on Wednesday amid retail investor interest in the stock.</li>
	<li>Express, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXPR#NYSE">EXPR</a>) fell 19.5% to close at $5.24 after the company announced an at-the-market equity offering for up to 15 million shares.</li>
	<li>AMC Entertainment Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) fell 17.9% to settle at $51.34. AMC Entertainment shares soared higher by over 95% on Wednesday amid renewed interest from retail investors. The company announced Tuesday that it raised $230.5 million in new equity from Mudrick Capital.</li>
	<li>FireEye Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEYE#NASDAQ">FEYE</a>) shares fell 17.6% to settle at $18.56 after the company announced the sale of FIreEye Products business to Symphony Technology Group for $1.2 billion.</li>
	<li>Credit Acceptance Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CACC#NASDAQ">CACC</a>) fell 16.2% to close at $385.26.</li>
	<li>American Superconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMSC#NASDAQ">AMSC</a>) shares declined 15.5% to settle at $12.76 after the company late Wednesday reported Q1 results..</li>
	<li>Day One Biopharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAWN#NASDAQ">DAWN</a>) fell 14.3% to close at $19.00. The company recently priced its IPO at $16 per share.</li>
	<li>GT Biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) fell 14% to settle at $16.31.</li>
	<li>InnSuites Hospitality Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHT#NYSE">IHT</a>) dipped 13.8% to close at $7.45.</li>
	<li>GSX Techedu Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOTU#NYSE">GOTU</a>) fell 13.8% to settle at $14.95.</li>
	<li>Reneo Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPHM#NASDAQ">RPHM</a>) declined 13.7% to close at $9.23.</li>
	<li>Hovnanian Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOV#NYSE">HOV</a>) dropped 13.6% to close at $118.17 following Q2 results.</li>
	<li>CooTek (Cayman) Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTK#NYSE">CTK</a>) shares fell 13.6% to settle at $1.78 as the company reported a first-quarter FY21 revenue decline of 24% year-on-year to $81.6 million, beating the analyst consensus of $80 million.</li>
	<li>SELLAS Life Sciences Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLS#NASDAQ">SLS</a>) dropped 13.5% to close at $10.90.</li>
	<li>TAL Education Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAL#NYSE">TAL</a>) tumbled 13.2% to close at $33.27.</li>
	<li>New Oriental Education &amp; Technology Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) dipped 12.1% to close at $9.32.</li>
	<li>Replimune Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) fell 12% to close at $31.90 as the company announced updated data from its Phase 2 skin cancer cohorts combining RP1 with Bristol-Myers Squibb Company&#39;s Opdivo and data from its Phase 1 study of RP2 alone and in combination with Opdivo, that continued to provide strong support for development in its lead indications.</li>
	<li>Singular Genomics Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMIC#NASDAQ">OMIC</a>) fell 10.4% to close at $27.73. The company recently priced its IPO at $22 a share.</li>
	<li>C3.ai, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) shares fell 10.4% to close at $68.26 after the company reported a loss for its fourth quarter.</li>
	<li>Splunk Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPLK#NASDAQ">SPLK</a>) shares dipped 9.5% to settle at $111.98 after the company reported worse-than-expected Q1 EPS results.</li>
	<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) dipped 8.5% to close at $258.18, selling off after the stock saw recent strength amid renewed interest in the name from retail investors on social media forums.</li>
	<li>Alpine Income Property Trust Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINE#NYSE">PINE</a>) fell 8.4% to close at $18.05 after the company announced a public offering of 2.5 million shares of common stock.</li>
</ul>

55 Biggest Movers From Yesterday

<h3>Gainers</h3>

<ul>
	<li>Orphazyme A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORPH#NASDAQ">ORPH</a>) surged 105% to $10.71.</li>
	<li>Medley Management Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLY#NASDAQ">MDLY</a>) shares jumped 78% to $10.39 after gaining 9% on Wednesday. Medley LLC recently received NYSE notice regarding delayed Form 10-Q filing.</li>
	<li>TRxADE HEALTH, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDS#NASDAQ">MEDS</a>) gained 63% to $6.65 as the company reported the launch of MedCheks Health Passport App for iOS devices.</li>
	<li>Sphere 3D Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANY#NASDAQ">ANY</a>) climbed 39% to $2.78 after jumping around 10% on Wednesday. Gryphon Digital Mining and Sphere 3D recently reported an agreement to purchase 250,000 Carbon Offset Credits.</li>
	<li>Yiren Digital Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YRD#NYSE">YRD</a>) gained 35% to $5.54 after reporting results for its first quarter.</li>
	<li>Orbsat Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSAT#NASDAQ">OSAT</a>) shares climbed 25% to $6.28.</li>
	<li>Support.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRT#NASDAQ">SPRT</a>) jumped 21% to $4.3095.</li>
	<li>Reneo Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPHM#NASDAQ">RPHM</a>) gained 20% to $11.69.</li>
	<li>Puhui Wealth Investment Management Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHCF#NASDAQ">PHCF</a>) gained 19.6% to $5.12.</li>
	<li>ZIVO Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZIVO#NASDAQ">ZIVO</a>) rose 18.2% to $5.79 after declining over 5% on Wednesday.</li>
	<li>Xinyuan Real Estate Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XIN#NYSE">XIN</a>) gained 16% to $2.98 after the company highlighted completion of five newly constructed properties.</li>
	<li>RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) shares rose 15% to $702.26 after the company reported stronger-than-expected results for its first quarter and boosted its FY21 sales forecast.</li>
	<li>Blue Apron Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APRN#NYSE">APRN</a>) gained 14.6% to $6.44.</li>
	<li>Verona Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>) jumped 14% to $7.42 after the company, and Nuance Pharma, announced the companies have entered into an agreement granting Nuance Pharma the rights to develop and commercialize</li>
	<li>ensifentrine in Greater China.</li>
	<li>ReneSola Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) gained 14% to $10.37.</li>
	<li>Signet Jewelers Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) surged 13.6% to $69.39 after the company reported better-than-expected Q1 results and issued strong revenue guidance.</li>
	<li>1stdibs.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DIBS#NASDAQ">DIBS</a>) gained 12.8% to $22.58 as the company priced its IPO at $20 a share.</li>
	<li>Exela Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XELA#NASDAQ">XELA</a>) rose 11.8% to $1.90 after gaining more than 8% on Wednesday.</li>
	<li>New Oriental Education &amp; Technology Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) rose 11% to $9.99 after gaining over 5% on Wednesday. Credit Suisse recently downgraded the stock from Outperform to Neutral.</li>
	<li>Alset EHome International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEI#NASDAQ">AEI</a>) rose 11% to $5.35 after dropping 4% on Wednesday.</li>
	<li>Puxin Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEW#NYSE">NEW</a>) gained 10.2% to $2.37.</li>
	<li>Oxford Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) shares climbed 9.2% to $107.08 after the company reported upbeat results for its first quarter and issued strong Q2 forecast. The company also boosted its FY21 sales guidance.</li>
	<li>TAL Education Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAL#NYSE">TAL</a>) rose 7.1% to $30.90.</li>
	<li>Invesco Mortgage Capital Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVR#NYSE">IVR</a>) rose 6.4% to $4.43. Invesco Mortgage Capital shares jumped over 17% on Wednesday amid increased retail investor interest in the stock.</li>
	<li>Asana, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) jumped 6.1% to $43.68 after the company CEO reported buying 500,000 shares of the stock.</li>
</ul>

 
<a href="https://www.benzinga.com/investing/best-penny-stocks/">Check out these big penny stock gainers and losers</a>

<h3>Losers</h3>

<ul>
	<li>Aethlon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares dipped 27.5% to $7.82 after the company reported a 1.38 million share offering at $9 per share. Aethlon Medical shares jumped 388% on Wednesday following a Zacks SCR article on Tuesday titled &#39;AEMD: First Ever In Vivo Removal Of COVID Virus From Bloodstream Of An Infected Patient.&#39;</li>
	<li>Washington Prime Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPG#NYSE">WPG</a>) fell 23.3% to $5.16 after jumping around 35% on Wednesday.</li>
	<li>Ocugen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) fell 23.3% to $7.15 after the company announced it will pursue a biologics license application path for its COVID-19 vaccine instead of emergency use authorization.</li>
	<li>KLX Energy Services Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLXE#NASDAQ">KLXE</a>) dipped 19.4% to $10.89 after the company late Wednesday reported worse-than expected Q1 results.</li>
	<li>The GEO Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) shares fell 17.7% to $7.25. GEO Group shares climbed 38% on Wednesday amid continued retail investor interest in high-short interest stocks.</li>
	<li>Materialise NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTLS#NASDAQ">MTLS</a>) fell 17.1% to $23.21 after the company reported pricing of public offering of 4.0 million American Depositary Shares.</li>
	<li>Sequential Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SQBG#NASDAQ">SQBG</a>) dropped 16.7% to $10.09.</li>
	<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) fell 15.4% to $256.05. GameStop reported a narrower-than-expected loss for its first quarter, while sales also exceeded estimates. GameStop also named Matt Furlong as its new CEO, while Mike Recupero was named as the company&rsquo;s CFO. The company suspended its guidance going forward. GameStop also disclosed that the U.S. Securities and Exchange Commission is investigating the retail trading frenzy.</li>
	<li>PLBY Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLBY#NASDAQ">PLBY</a>) fell 14.9% to $43.58.</li>
	<li>Celsius Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) shares fell 14.8% to $61.95 after the company reported pricing of public offering of common stock.</li>
	<li>Aterian, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATER#NASDAQ">ATER</a>) dipped 13.7% to $16.14 as the company reported pricing of $40 million private placement.</li>
	<li>Energous Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WATT#NASDAQ">WATT</a>) fell 13.1% to $2.92. Energous and Atomosic Technologies, recently announced they have achieved the industry&#39;s first interoperability for radio frequency energy harvesting technology.</li>
	<li>REV Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVG#NASDAQ">REVG</a>) dropped 13% to $16.90 after the company announced a proposed secondary offering of 7.5 million shares of common stock.</li>
	<li>Lakeland Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAKE#NASDAQ">LAKE</a>) fell 12% to $23.25 following Q1 results.</li>
	<li>AMC Entertainment Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) shares fell 10.8% to $44.02 after dropping over 10% on Wednesday.</li>
	<li>SPI Energy Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPI#NASDAQ">SPI</a>) fell 10.4% to $7.16 after jumping 28% on Wednesday. SPI Energy group company, Phoenix Motorcars, had commenced production of its first third-generation drivetrain products.</li>
	<li>Clover Health Investments, Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) fell 8% to $15.60 after tumbling around 24% on Wednesday.</li>
</ul>

42 Stocks Moving In Thursday's Mid-Day Session

&nbsp;

<h3>Gainers</h3>

<ul>
	<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares moved upwards by 16.17% to $3.16 during Thursday&#39;s regular session. NuCana&#39;s stock is trading at a volume of 4.7 million shares as of 12:30 EST. This is 1352.46% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $164.8 million.</li>
	<li>Reneo Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPHM#NASDAQ">RPHM</a>) shares increased by 12.64% to $10.96. As of 12:30 EST, this security is trading at a volume of 137.8K shares, making up 107.63% of its average full-day volume over the last 100 days.</li>
	<li>Axcella Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXLA#NASDAQ">AXLA</a>) shares increased by 11.3% to $3.84. The current volume of 309.5K shares is 370.15% of Axcella Health&#39;s average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $144.8 million.</li>
	<li>Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) shares increased by 10.21% to $19.58. Aclaris Therapeutics&#39;s stock is trading at a volume of 1.7 million shares as of 12:30 EST. This is 275.42% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.0 billion.</li>
	<li>Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) stock rose 9.73% to $22.65. Trading volume for this security as of 12:30 EST is 2.7 million, which is 75.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.4 billion.</li>
	<li>Aptinyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTX#NASDAQ">APTX</a>) stock increased by 9.11% to $3.1. As of 12:30 EST, Aptinyx&#39;s stock is trading at a volume of 1.4 million, which is 350.74% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $211.2 million.</li>
</ul>

&nbsp;

&nbsp;

<h3>Losers</h3>

&nbsp;

<ul>
	<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock declined by 26.88% to $7.89 during Thursday&#39;s regular session. Trading volume for Aethlon Medical&#39;s stock is 17.3 million as of 12:30 EST. This is 395.54% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $95.7 million.</li>
	<li>Ocugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) shares declined by 23.9% to $7.08. As of 12:30 EST, Ocugen&#39;s stock is trading at a volume of 107.7 million, which is 170.23% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.4 billion.</li>
	<li>Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) stock decreased by 16.66% to $1.05. As of 12:30 EST, Regulus Therapeutics&#39;s stock is trading at a volume of 61.8 million, which is 2343.47% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $78.6 million.</li>
	<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares declined by 12.17% to $1.95. The current volume of 421.5K shares is 82.14% of SCWorx&#39;s average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $19.5 million.</li>
	<li>Progenity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROG#NASDAQ">PROG</a>) stock declined by 9.52% to $2.42. As of 12:30 EST, this security is trading at a volume of 2.4 million shares, making up 307.16% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $146.6 million.</li>
	<li>Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) stock fell 8.83% to $9.14. Inovio Pharmaceuticals&#39;s stock is trading at a volume of 5.8 million shares as of 12:30 EST. This is 67.99% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.9 billion.</li>
</ul>

&nbsp;

&nbsp;

<h3>Gainers</h3>

<ul>
	<li>Orphazyme A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORPH#NASDAQ">ORPH</a>) shares jumped 302.3% to close at $21.00 on Thursday. Shares of the biopharmaceutical firm touched an intraday high of $77.77, running up 1,387%. On May 7, in the latest press statement put out by Orphazyme, it said its application for arimoclomol, which will be branded as MIPLYFFA for Niemann-Pick disease type C, is under priority review with the U.S. Food and Drug Administration &mdash; with the expected Prescription Drug User Fee Act action date of June 17.</li>
	<li>TRxADE HEALTH, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDS#NASDAQ">MEDS</a>) climbed 63.5% to settle at $6.67 as the company reported the launch of MedCheks Health Passport App for iOS devices.</li>
	<li>Sphere 3D Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANY#NASDAQ">ANY</a>) jumped 60.5% to close at $3.21 after jumping around 10% on Wednesday. Gryphon Digital Mining and Sphere 3D recently reported an agreement to purchase 250,000 Carbon Offset Credits.</li>
	<li>Galecto, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLTO#NASDAQ">GLTO</a>) gained 60% to settle at $8.00.</li>
	<li>Axcella Health Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXLA#NASDAQ">AXLA</a>) jumped 48.7% to close at $5.13. Traders circulated TipRanks report &#39;2 &quot;Strong Buy&quot; Penny Stocks That Could Rally to $10 (or More).&#39;</li>
	<li>1stdibs.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DIBS#NASDAQ">DIBS</a>) surged 42.5% to close at $28.50 as the company priced its IPO at $20 a share.</li>
	<li>Heat Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTBX#NASDAQ">HTBX</a>) rose 40.2% to settle at $9.60 after the company filed for a patent titled &ldquo;GP96-Based Cancer Therapy.&rdquo;</li>
	<li>Medley Management Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLY#NASDAQ">MDLY</a>) shares gained 36.6% to settle at $7.98 after gaining 9% on Wednesday. Medley LLC recently received NYSE notice regarding delayed Form 10-Q filing.</li>
	<li>Yiren Digital Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YRD#NYSE">YRD</a>) rose 29.4% to close at $5.32 after reporting results for its first quarter.</li>
	<li>Digital Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) jumped 27.3% to close at $4.01.</li>
	<li>Orbsat Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSAT#NASDAQ">OSAT</a>) shares gained 25.5% to close at $6.31.</li>
	<li>Amesite Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMST#NASDAQ">AMST</a>) jumped 25.3% to settle at $2.77.</li>
	<li>Puhui Wealth Investment Management Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHCF#NASDAQ">PHCF</a>) rose 23.1% to close at $5.27.</li>
	<li>Graybug Vision, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAY#NASDAQ">GRAY</a>) jumped 22.5% to settle at $5.53.</li>
	<li>Support.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRT#NASDAQ">SPRT</a>) gained 22.3% to close at $4.33.</li>
	<li>LifeStance Health Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFST#NASDAQ">LFST</a>) surged 21.7% to settle at $21.90 as the company priced its IPO at $18 per share.</li>
	<li>GBS Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBS#NASDAQ">GBS</a>) gained 19% to close at $3.63.</li>
	<li>Senseonics Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SENS#NYSE">SENS</a>) surged 17.9% to settle at $3.62. Senseonics Holdings has been earmarked by Reddit traders and institutions alike for the large amount of short interest on its stock.</li>
	<li>Terns Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TERN#NASDAQ">TERN</a>) gained 17.6% to close at $19.34.</li>
	<li>Biomerica, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) gained 17.2% to settle at $4.63.</li>
	<li>NuCana plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) jumped 16.9% to close at $3.18.</li>
	<li>RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) shares jumped 15.7% to close at $707.14 after the company reported stronger-than-expected results for its first quarter and boosted its FY21 sales forecast.</li>
	<li>monday.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) rose 15.4% to close at $178.87 after the company priced its IPO at $155 a share.</li>
	<li>Embraer S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERJ#NYSE">ERJ</a>) surged 15.3% to close at $15.72 after the company confirmed its Eve subsidiary started negotiations related to a possible business combination with Zanite Acquisition.</li>
	<li>Alset EHome International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEI#NASDAQ">AEI</a>) gained 14.9% to settle at $5.54 after dropping 4% on Wednesday.</li>
	<li>Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) jumped 14.3% to close at $44.52. HC Wainwright &amp; Co. maintained Prothena with a Buy and raised the price target from $33 to $58.</li>
	<li>MediWound Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) surged 14.3% to close at $4.57. MediWound said it completed patient enrollment for interim assessment of U.S. EscharEx Phase 2 Adaptive Design Study.</li>
	<li>Churchill Capital Corp II (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCX#NYSE">CCX</a>) rose 14.2% to settle at $11.61.</li>
	<li>Xinyuan Real Estate Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XIN#NYSE">XIN</a>) gained 14.1% to close at $2.93 after the company highlighted completion of five newly constructed properties.</li>
	<li>Signet Jewelers Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) jumped 14% to close at $69.58 after the company reported better-than-expected Q1 results and issued strong revenue guidance.</li>
	<li>Data Storage Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTST#NASDAQ">DTST</a>) surged 13.4% to close at $6.10.</li>
	<li>Verona Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>) gained 13.2% to close at $7.37 after the company, and Nuance Pharma, announced the companies have entered into an agreement granting Nuance Pharma the rights to develop and commercialize ensifentrine in Greater China.</li>
	<li>Aptinyx Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTX#NASDAQ">APTX</a>) rose 13% to close at $3.21. Traders circulated TipRanks report &#39;2 &quot;Strong Buy&quot; Penny Stocks That Could Rally to $10 (or More).&#39;</li>
	<li>Asana, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) jumped 11.6% to settle at $45.94 after the company CEO reported buying 500,000 shares of the stock.</li>
	<li>Reneo Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPHM#NASDAQ">RPHM</a>) rose 10.1% to close at $10.71.</li>
	<li>Oxford Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) shares gained 8.2% to settle at $106.10 after the company reported upbeat results for its first quarter and issued strong Q2 forecast. The company also boosted its FY21 sales guidance.</li>
	<li>New Oriental Education &amp; Technology Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) climbed 7.9% to close at $9.73 after gaining over 5% on Wednesday. Credit Suisse recently downgraded the stock from Outperform to Neutral.</li>
	<li>TAL Education Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAL#NYSE">TAL</a>) gained 7.7% to close at $31.07.</li>
	<li>Blue Apron Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APRN#NYSE">APRN</a>) rose 7.3% to close at $6.03.</li>
	<li>ZIVO Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZIVO#NASDAQ">ZIVO</a>) gained 6.3% to close at $5.21 after declining over 5% on Wednesday.</li>
</ul>

&nbsp;

 
<a href="https://www.benzinga.com/investing/best-penny-stocks/">Check out these big penny stock gainers and losers</a>

<h3>Losers</h3>

<ul>
	<li>Aethlon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares tumbled 36.1% to settle at $6.90 on Thursday after the company reported a 1.38 million share offering at $9 per share. Aethlon Medical shares jumped 388% on Wednesday following a Zacks SCR article on Tuesday titled &#39;AEMD: First Ever In Vivo Removal Of COVID Virus From Bloodstream Of An Infected Patient.&#39;</li>
	<li>Ocugen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) dipped 28.1% to close at $6.69 after the company announced it will pursue a biologics license application path for its COVID-19 vaccine instead of emergency use authorization.</li>
	<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) fell 27.2% to close at $220.39. GameStop reported a narrower-than-expected loss for its first quarter, while sales also exceeded estimates. GameStop also named Matt Furlong as its new CEO, while Mike Recupero was named as the company&rsquo;s CFO. The company suspended its guidance going forward. GameStop also disclosed that the U.S. Securities and Exchange Commission is investigating the retail trading frenzy.</li>
	<li>Washington Prime Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPG#NYSE">WPG</a>) dropped 24.8% to close at $5.06 after jumping around 35% on Wednesday.</li>
	<li>KLX Energy Services Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLXE#NASDAQ">KLXE</a>) dipped 24.2% to close at $10.24 after the company late Wednesday reported worse-than expected Q1 results.</li>
	<li>Jiuzi Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZXN#NASDAQ">JZXN</a>) fell 20.2% to close at $9.50.</li>
	<li>The GEO Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) shares slipped 19.9% to close at $7.05. GEO Group shares climbed 38% on Wednesday amid continued retail investor interest in high-short interest stocks.</li>
	<li>Birks Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGI#NYSE">BGI</a>) fell 19.3% to settle at $3.14.</li>
	<li>Sequential Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SQBG#NASDAQ">SQBG</a>) fell 19% to close at $9.82.</li>
	<li>Materialise NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTLS#NASDAQ">MTLS</a>) fell 18.3% to close at $22.89 after the company reported pricing of public offering of 4.0 million American Depositary Shares.</li>
	<li>REV Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVG#NASDAQ">REVG</a>) dipped 17.6% to close at $16.00 after the company announced a proposed secondary offering of 7.5 million shares of common stock.</li>
	<li>PLBY Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLBY#NASDAQ">PLBY</a>) fell 16.1% to close at $42.97.</li>
	<li>Aterian, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATER#NASDAQ">ATER</a>) fell 16% to close at $15.70 as the company reported pricing of $40 million private placement.</li>
	<li>IDT Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDT#NYSE">IDT</a>) dropped 15.7% to settle at $34.55.</li>
	<li>Clean Energy Fuels Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNE#NASDAQ">CLNE</a>) dropped 15.6% to settle at $10.99.</li>
	<li>Clover Health Investments, Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) fell 15.3% to close at $14.34 after tumbling around 24% on Wednesday.</li>
	<li>Celsius Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) shares tumbled 15.1% to close at $61.75 after the company reported pricing of public offering of common stock.</li>
	<li>Nemaura Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRD#NASDAQ">NMRD</a>) dropped 14.4% to settle at $12.94.</li>
	<li>Metromile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MILE#NASDAQ">MILE</a>) fell 14.1% to close at $10.39.</li>
	<li>Takung Art Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKAT#NASDAQ">TKAT</a>) shares declined 13.6% to settle at $18.94.</li>
	<li>AMC Entertainment Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) shares fell 13.2% to settle at $42.81 after dropping over 10% on Wednesday.</li>
	<li>Enthusiast Gaming Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGLX#NASDAQ">EGLX</a>) shares dropped 13.2% to close at $6.11 as the company launched 8 million share common stock offering.</li>
	<li>Lakeland Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAKE#NASDAQ">LAKE</a>) fell 12.6% to close at $23.11 following Q1 results.</li>
	<li>Hawaiian Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HA#NASDAQ">HA</a>) tumbled 12.4% to settle at $26.20. MKM Partners initiated coverage on Hawaiian Holdings with a Neutral rating and announced a price target of $27.</li>
	<li>Energous Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WATT#NASDAQ">WATT</a>) fell 11.9% to close at $2.96. Energous and Atomosic Technologies, recently announced they have achieved the industry&#39;s first interoperability for radio frequency energy harvesting technology.</li>
	<li>SPI Energy Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPI#NASDAQ">SPI</a>) fell 8.3% to close at $7.33 after jumping 28% on Wednesday. SPI Energy group company, Phoenix Motorcars, had commenced production of its first third-generation drivetrain products.</li>
</ul>

66 Biggest Movers From Yesterday

<h3>Gainers</h3>

<ul>
	<li>CAI International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAI#NYSE">CAI</a>) shares surged 46.9% to close at $56.05 on Friday after the company agreed to a $1.1 billion takeover by Mitsubishi HC Capital Inc.</li>
	<li>Sykes Enterprises, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYKE#NASDAQ">SYKE</a>) rose 29.8% to settle at $53.45 after the company announced it will be acquired by Sitel Group at a purchase price of $54 per share in cash.</li>
	<li>Geron Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) shares gained 29.8% to close at $1.83 after the company reported the publication of IMbark Phase 2 data in the Journal of Clinical Oncology.</li>
	<li>ATAI Life Sciences N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) surged 29.7% to settle at $19.45 after the company priced its IPO at $15 per share.</li>
	<li>Alfi, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALF#NASDAQ">ALF</a>) gained 29.4% to close at $7.96. The company, last week, announced an agreement with All-Niter for the fulfillment, staging and shipment of 10,000 digital tablets to countrywide Uber and Lyft drivers.</li>
	<li>Verve Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) climbed 19.2% to close at $38.05. Verve Therapeutics shares surged 68% on Thursday after the company priced its IPO at $19 per share.</li>
	<li>Smith &amp; Wesson Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWBI#NASDAQ">SWBI</a>) gained 17.2% to settle at $23.35 after the company posted better-than-expected results for its fourth quarter. The company reported a $50 million buyback program and also boosted its quarterly dividend from $0.05 to $0.08 per share.</li>
	<li>Torchlight Energy Resources, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRCH#NASDAQ">TRCH</a>) surged 16.1% to close at $6.27.</li>
	<li>PDS Biotechnology Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) jumped 15.8% to close at $11.52 after multiple officers and directors reported shares purchases in Form 4 Filings on Thursday.</li>
	<li>Codex DNA, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNAY#NASDAQ">DNAY</a>) climbed 15.6% to close at $18.50 after the company priced its IPO at $16 per share.</li>
	<li>Century Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPSC#NASDAQ">IPSC</a>) gained 14.2% to settle at $22.83 as the company priced its IPO at $20 a share.</li>
	<li>Quantum-Si incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) surged 13.8% to close at $9.22.</li>
	<li>Aptorum Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) rose 13.2% to close at $3.43.</li>
	<li>KnowBe4, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNBE#NASDAQ">KNBE</a>) surged 12.9% to close at $33.66.</li>
	<li>&nbsp;</li>
	<li>Codexis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) shares gained 12.6% to settle at $22.12 after the company lifted its sales projections for 2021 following the receipt of a new order for a proprietary high performance enzyme product. The company said it now expects revenue of $89 million to $93 million, versus its earlier forecast of $82 million to $85 million.</li>
	<li>Vallon Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLON#NASDAQ">VLON</a>) surged 11.5% to close at $5.34.</li>
	<li>Wah Fu Education Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAFU#NASDAQ">WAFU</a>) gained 11.4% to settle at $8.13. Wah Fu Education recently filed for mixed shelf of up to $25 million.</li>
	<li>Intec Pharma Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTEC#NASDAQ">NTEC</a>) gained 10.2% to close at $4.96.</li>
	<li>TRACON Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) jumped 10.1% to close at $7.26.</li>
	<li>Crinetics Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNX#NASDAQ">CRNX</a>) rose 9.7% to close at $21.15 after JP Morgan upgraded the stock from Neutral to Overweight and announced a $28 price target.</li>
	<li>Cyanotech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYAN#NASDAQ">CYAN</a>) gained 9.2% to settle at $2.98.</li>
	<li>DLocal Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLO#NASDAQ">DLO</a>) climbed 9.1% to close at $37.58. DLocal, earlier during the month, priced its IPO at $21 a share.</li>
	<li>SemiLEDs Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEDS#NASDAQ">LEDS</a>) climbed 7.9% to settle at $19.35.</li>
	<li>CureVac N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) gained 7.1% to close at $61.94. CureVac shares tumbled 39% on Thursday after the company announced its COVID-19 vaccine demonstrated an interim vaccine efficacy of 47% and did not meet its prespecified statistical success criteria.</li>
	<li>The GEO Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) shares rose 5.8% to close at $7.62 after an SEC Form 4 filing showed the CEO George Zoley bought 166K shares of the stock at an average price of $6.7452 per share on June 15th.</li>
	<li>AnPac Bio-Medical Science Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANPC#NASDAQ">ANPC</a>) gained 5.8% to close at $4.58 after the company announced it was granted its first disease treatment patent by the USPTO on June 7, 2021. The company also announced it cancer treatment project secured multi-million dollar funds.</li>
	<li>Hydrofarm Holdings Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYFM#NASDAQ">HYFM</a>) shares rose 3.8% to close at $56.50 after the company announced plans to acquire Aurora Innovations, Inc. and its organic nutrients and grow media operations.</li>
</ul>

&nbsp;

<a href="https://www.benzinga.com/investing/best-penny-stocks/">Check out these big penny stock gainers and losers</a>

<h3>Losers</h3>

<ul>
	<li>Orphazyme A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORPH#NASDAQ">ORPH</a>) shares fell 49.7% to close at $7.33 on Friday after the company announced it received a Complete Response Letter from the FDA for its treatment for Niemann-Pick Disease Type C and also cut its FY2021 outlook.</li>
	<li>Athira Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) dropped 38.9% to settle at $11.15. Athira Pharma&rsquo;s CEO Leen Kawas has been placed on temporary leave until the company completes a review &ldquo;stemming from doctoral research Dr. Kawas conducted while at Washington State University.&rdquo; The company, which is developing drugs for treating Alzheimer&rsquo;s disease, said that Chief Operating Officer Mark Litton would assume day-to-day responsibilities during Kawas&rsquo; leave.</li>
	<li>Urban One, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UONE#NASDAQ">UONE</a>) tumbled 28% to close at $9.84 as the stock continues to pull back after it saw a run up in anticipation of Juneteenth in recent weeks. The company late Wednesday filed a prospectus related to the offer and sale of 2.9 million shares.</li>
	<li>Capstone Green Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGRN#NASDAQ">CGRN</a>) shares fell 22.3% to close at $5.69 after the company increased its earlier announced bought deal offering of common stock to $10.0 million.</li>
	<li>Oxbridge Re Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OXBR#NASDAQ">OXBR</a>) fell 21.5% to close at $2.66.</li>
	<li>MediaCo Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDIA#NASDAQ">MDIA</a>) dipped 20.2% to close at $3.92.</li>
	<li>AGM Group Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGMH#NASDAQ">AGMH</a>) fell 19.4% to close at $10.40.</li>
	<li>Nouveau Monde Graphite Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NMG#NYSE">NMG</a>) dipped 17.7% to settle at $7.45 after the company reported pricing of $52,500,000 public offering of common shares in the US and Canada.</li>
	<li>Reneo Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPHM#NASDAQ">RPHM</a>) tumbled 17.3% to close at $8.63.</li>
	<li>Broadway Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYFC#NASDAQ">BYFC</a>) dropped 16.6% to settle at $2.51. The financial sector was pressured by a dip in the 10-year and 30-year treasury yields.</li>
	<li>Townsquare Media, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSQ#NYSE">TSQ</a>) declined 14.8% to close at $11.56.</li>
	<li>Entera Bio Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTX#NASDAQ">ENTX</a>) fell 14.8% to close at $4.42.</li>
	<li>CuriosityStream Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURI#NASDAQ">CURI</a>) fell 14.7% to close at $12.63. B of A Securities downgraded CuriosityStream from Buy to Underperform.</li>
	<li>Arrival (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVL#NASDAQ">ARVL</a>) fell 14.2% to close at $17.91. Arrival recently reiterated plans to have 31 microfactories by the end of 2024 and may add more if the demand is high.</li>
	<li>Engine Media Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAME#NASDAQ">GAME</a>) dipped 14% to close at $9.00.</li>
	<li>San Juan Basin Royalty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJT#NYSE">SJT</a>) fell 13.4% to close at $4.84. San Juan Basin Royalty Trust declared cash distribution of $0.017615 per unit for June 2021.</li>
	<li>Nam Tai Property Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTP#NYSE">NTP</a>) dipped 13.3% to settle at $26.80 on below-average volume.</li>
	<li>Vivos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) fell 13% to close at $4.94.</li>
	<li>Protagenic Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) dropped 12.8% to close at $2.94.</li>
	<li>Carver Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARV#NASDAQ">CARV</a>) dipped 12.4% to close at $10.01.</li>
	<li>Diginex Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQOS#NASDAQ">EQOS</a>) fell 12.4% to settle at $6.81.</li>
	<li>inTEST Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INTT#NYSE">INTT</a>) dropped 12.2% to close at $15.58.</li>
	<li>Graybug Vision, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAY#NASDAQ">GRAY</a>) fell 12% to settle at $5.05.</li>
	<li>Ares Commercial Real Estate Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACRE#NYSE">ACRE</a>) shares fell 11.4% to close at $14.45 after the company priced an underwritten public offering of 6,500,000 shares for total estimated gross proceeds of around $102.8 million.</li>
	<li>Olema Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLMA#NASDAQ">OLMA</a>) tumbled 11.2% to settle at $24.51.</li>
	<li>Thryv Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRY#NASDAQ">THRY</a>) dipped 10.4% to close at $31.91.</li>
	<li>Cuentas Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUEN#NASDAQ">CUEN</a>) fell 9.5% to settle at $2.28.</li>
	<li>Unisys Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UIS#NYSE">UIS</a>) dropped 9.2% to close at $24.06.</li>
	<li>Tenneco Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEN#NYSE">TEN</a>) fell 8.7% to close at $19.81.</li>
	<li>Auddia Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUUD#NASDAQ">AUUD</a>) shares declined 8.6% to settle at $2.55.</li>
	<li>Cellect Biotechnology Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APOP#NASDAQ">APOP</a>) fell 5.8% to close at $3.91. Cellect Biotechnology shares jumped 27% on Thursday after the company announced it filed a registration statement in connect with the proposed merger agreement with Quoin Pharmaceuticals.</li>
</ul>

Q2 2021		Est.		Actual		Surprise
EPS		(EXPECTED)2021-08-22
REV		(EXPECTED)2021-08-22

Q1 2021		Est.		Actual		Surprise
EPS				-3.480
REV				0

Recent Quotes

Earnings

Analyst Ratings

Related Companies

Reneo Pharmaceuticals Frequently Asked Questions

How do I buy Reneo Pharmaceuticals (RPHM) stock?

Who are Reneo Pharmaceuticals's (RPHM) competitors?

What is the target price for Reneo Pharmaceuticals (RPHM) stock?

Current Stock Price for Reneo Pharmaceuticals (RPHM)?

Does Reneo Pharmaceuticals (RPHM) pay a dividend?

When is Reneo Pharmaceuticals (NASDAQ:RPHM) reporting earnings?

Is Reneo Pharmaceuticals (RPHM) going to split?

What sector and industry does Reneo Pharmaceuticals (RPHM) operate in?